☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report(s)), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November 13, 2018,~~August 14, 2019, the registrant had ~~72,088,603~~75,747,718 shares of its common stock, par value $0.001 per share, outstanding.

Helix TCS, Inc., (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment No. 1”) to its quarterly report on Form 10-Q for the period ended September 30, 2018, which was originally filed with the Securities and Exchange Commission (“SEC”) on November 14, 2018 (the “Original Filing”). The Company is filing this Amendment No. 1 to reflect the correction of an error regarding the understatement of cost of revenue for the three months ended September 30, 2018. The Company has made the requisite correction to the financial statements and related footnote disclosures and updated the Management Discussion and Analysis Section accordingly. This Amendment No. 1 amends information in Part 1, Item 1 and Item 2, along with Part 2, Item 6. All other information and items as presented in the Original Filing and as included herein are unchanged. Except for the foregoing, this Amendment No. 1 does not amend, update or change any other information presented in the Original Filing. This Amendment No. 1 also includes updated information of the preceding cover page, this explanatory note, the signature page and certifications required to be filed as exhibits.

See accompanying notes to the unaudited condensed consolidated financial statements

See accompanying notes to the unaudited condensed consolidated financial statements.

CONDENSED CONSOLIDATED ~~STATEMENT~~STATEMENTS OF ~~SHAREHOLDERS’ EQUITY~~CASH FLOWS

See accompanying notes to the unaudited condensed consolidated financial statements.

HELIX TCS, INC.

~~CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS~~

~~(UNAUDITED)~~

For the Nine Months Ended
September 30,
2018 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (4,945,477 ) $ (8,120,027 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 1,869,889 292,757
Amortization of debt discounts - 244,843
Share-based compensation expense 2,143,548 -
Change in fair value of convertible notes (504,768 ) 210,000
Change in fair value of obligation to issue warrants (1,434,760 ) (406,604 )
Change in fair value of convertible notes - related party (93,506 ) (8,971 )
Change in fair value of contingent consideration 131,994 (10,186 )
Loss on induced conversion of convertible debt - 1,503,876
Loss on extinguishment of debt - 4,611,395
Loss on beneficial conversion feature of convertible note - 390,666
Loss on impairment of goodwill 664,329 -
Gain on reduction of obligation pursuant to acquisition (607,415 ) -
Change in operating assets and liabilities:
Accounts receivable (373,314 ) (246,375 )
Prepaid expenses - -
Deposits (87,161 ) (14,640 )
Costs in excess of billings 16,055 (54,547 )
Accounts payable and accrued expenses 26,044 122,875
Deferred rent (6,403 ) 3,002
Billings in excess of costs (16,405 ) 29,270
Net cash used in operating activities (3,217,350 ) (1,452,666 )

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment (85,665 ) (31,054 )
Payments for business combination, net of cash acquired (79,664 ) (1,631,313 )
Cash acquired as part of business combination 454,306 -
Payments for asset acquisition (58,729 ) (46,872 )
Net cash provided by (used in) investing activities 230,248 (1,709,239 )

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of convertible notes payable - 229,167
Payments pursuant to convertible notes payable - related party (150,000 ) -
(Repayments to)/advances from related parties (69,500 ) 60,500
Repayment to related parties - (32,000 )
Payments pursuant to notes payable - (3,466 )
Proceeds from notes payable 16,271 -
Proceeds from the issuance of a promissory note 250,000 255,000
Proceeds from the issuance of common stock 2,595,214 100,000
Proceeds from the issuance of Series B convertible preferred stock - 2,624,988
Net cash provided by financing activities 2,641,985 3,234,189

Effect of foreign exchange rate changes on cash (58,445 ) -
Net change in cash (403,562 ) 72,284
Cash, beginning of period 868,554 57,841
Cash, end of period $ 464,992 $ 130,125

Supplemental disclosure of cash and non-cash transactions:
Financing of property and equipment purchases $ - $ 52,082
Equity issuance pursuant to asset acquisition (non-cash acquisition of BioTrack) $ 57,552,033 $ -
Equity issuance pursuant to asset acquisition (non-cash acquisition of Engeni) $ 1,166,000 $ -
Cost of issuance of Series B preferred shares $ - $ (1,941,633 )
Stock options issued pursuant to acquisition consideration $ - $ 916,643
Stock options issued pursuant to contingent consideration as part of acquisition $ - $ 871,193
Warrant issuances to investors $ - $ 93,200
Reacquisition price of convertible debt $ - $ 4,581,395
Partial conversion of convertible note into common stock $ 175,000 $ -

~~See accompanying notes to the unaudited condensed consolidated financial statements.~~

~~HELIX TCS, INC.~~

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1.	Description of Business

Helix TCS, Inc. (the “Company” or “Helix”) was incorporated in Delaware on March 13, 2014. Pursuant to the acquisition of the assets of Helix TCS, LLC, as discussed below, we changed our name from Jubilee4 Gold, Inc. to Helix TCS, Inc. effective October 25, 2015.

Effective October 25, 2015, we entered into an acquisition and exchange agreement with Helix TCS, LLC. We closed the transaction contemplated under the acquisition and exchange agreement on December 23, 2015 and Helix TCS, LLC was merged into and with Helix.

Effective October 1, 2015, for accounting purposes, as part of an acquisition amounting to a reorganization dated December 21, 2015, Helix Opportunities LLC exchanged 100% of Helix TCS, LLC and its wholly-owned subsidiaries, Security Consultants Group, LLC and Boss Security Solutions, Inc. to the Company in exchange for 20 million common shares and 1 million convertible preferred shares of the Company.

The acquisition of Helix was treated as a recapitalization for financial accounting purposes. Jubilee4 Gold, Inc. is considered the acquiree for accounting purposes and their historical financial statements before the Acquisition Agreement were replaced with the historical financial statements of the Company. The common stock account of the Company continues post-merger, while the retained earnings of the acquiree is eliminated. Furthermore, on April 11, 2016, the Company acquired the assets of Revolutionary Software, LLC (“Revolutionary”) ~~(see Note 7)~~.

On June 2, 2017 (the “Closing”), the Company entered into a Membership Interest Purchase Agreement (the “Agreement”) in which the Company purchased all issued and outstanding Units of Security Grade Protective Services, Ltd. (“Security Grade”), which consisted of 800,000 Class A Units and 200,000 Class B Units. At closing, the Company delivered $800,000 in cash and 207,427 non-qualified stock options (the “Initial Stock Options”). Furthermore, provided that, within the first 60 days following the Closing, no material customer identified in the Agreement terminates its contractual relationship with the Company and that all contracts with such material customers are in full force and effect without default or cancellation as of the 60^th ~~day following the Closing, on the 61~~^st day following the Closing, the Company shall issue 207,427 additional stock options (the “Additional Stock Options”). The Company subsequently issued the 207,427 additional stock options on August 1, 2017 as well as a second cash payment of $800,000 pursuant to the original terms of the Agreement.

In the first quarter of 2018, the Company notified the selling members of Security Grade of their intent to exercise their right of setoff noted in the Agreement after discovering misrepresentations made by one of the selling members of Security Grade. The Company has settled with all of the six selling members. See~~Note 6for further details surrounding the settlements.~~

On March 3, 2018, Helix, Inc. and its wholly owned subsidiary, Helix Acquisition Sub, Inc. (“Merger Sub”), entered into an Agreement and Plan of Merger (the ~~“BioTrack Merger~~“Merger Agreement”) with Bio-Tech Medical Software, Inc. (“BioTrackTHC”) and Terence J. Ferraro, as the representative of the BioTrackTHC ~~shareholders. Pursuant~~shareholders, pursuant to ~~the BioTrackTHC Merger Agreement, subject to the satisfaction or waiver of specified conditions,~~which Merger Sub ~~will merge~~merged with and into BioTrackTHC ~~with BioTrackTHC surviving the merger as a wholly-owned subsidiary of the Company.~~(the “Merger”).

On June 1, 2018 (the “BioTrackTHC Closing Date”), in connection with closing the Merger, the Company issued 38,184,985 unregistered shares of its common stock to BioTrackTHC stockholders, of which 1,852,677 shares were held back to satisfy indemnification obligations in the Merger Agreement, if necessary. The Company also assumed the Bio-Tech Medical Software, Inc. 2014 Stock Incentive Plan (“BioTrackTHC Stock Plan”), pursuant to which options exercisable in the amount of 8,132,410 shares of common stock are outstanding. As a result, BioTrackTHC stockholders will own 48% of the Company on a fully diluted basis on the BioTrackTHC Closing Date.

On August 3, 2018 (the “Engeni Closing Date”), the Company and its wholly owned subsidiary, Engeni Merger Sub, LLC (“Engeni Merger Sub”), entered into an Agreement and Plan of Merger (the “Engeni Merger Agreement”) with Engeni LLC (“Engeni US”), Engeni S.A (“Engeni SA”), Scott Zienkewicz, Nicolas Heller and Alberto Pardo Saleme (the Engeni US members), and Scott Zienkewicz, as the representative of the Engeni US ~~member.~~members. Pursuant to the Engeni Merger Agreement, Engeni Merger Sub merged with and into Engeni US, with Engeni US surviving the merger as a wholly-owned subsidiary of the Company (the “Engeni Merger”).

On the Engeni Closing Date, in connection with closing the Engeni Merger Agreement, the Company issued 366,700 shares of Company common stock to Engeni US members. Furthermore, the Company ~~will also issue~~subsequently issued Engeni US members ~~366,700 and 366,600~~733,300 shares of Company common stock ~~upon achievement of specific objectives. If applicable,~~on April 2, 2019.

On February 5, 2019, the Company and its wholly owned subsidiary, Merger Sub, entered into an Agreement and Plan of Merger (the “Amercanex Merger Agreement”) with Green Tree International, Inc., a corporation incorporated under the laws of the state of Colorado operating under the tradename “Amercanex International Exchange” (“Amercanex”). Pursuant to the Amercanex Merger Agreement, subject to the satisfaction or waiver of specified conditions, Merger Sub will ~~pay Engeni US members~~merge with and into Amercanex, with Amercanex surviving the ~~aggregate amount~~merger as a wholly-owned subsidiary of ~~$100,000, on a pro rata basis, if Engeni SA reaches financial breakeven on or before December 31, 2018, as determined by~~ the ~~Company’s Chief Financial Officer and Scott Zienkewicz.~~Company. The Merger is expected to close during the third quarter of 2019.

On April 1, 2019 (“Tan Security Closing Date”), the Company entered into a Membership Interest and Stock Purchase Agreement (the “Tan Security Acquisition Agreement”) with Tan’s International Security and Tan’s International LLC (collectively, “Tan Security”). Pursuant to the Tan Security Acquisition Agreement, the Company purchased all membership interests and capital stock of Tan Security and collectively holds 100% of the interests of Tan Security (the “Tan Security Acquisition”).

2.	~~Revision of Prior Period Financial Statements~~

The Company corrected certain immaterial errors in its financial statements contained herein. In accordance with ASC 650-10-S99 and S55 (formerly Staff Accounting Bulletins (“SAB”) No. 99 and No. 108), Accounting Changes and Error Corrections, the Company concluded that these errors were, individually, and in the aggregate, not material, quantitatively or qualitatively, to the financial statements in these periods.

On May 17, 2017, the Company sold to accredited investors an aggregate of 5,781,426 Series B Preferred Shares for gross proceeds of $1,875,000 and converted a $500,000 Unsecured Convertible Promissory Note into 1,536,658 Series B Preferred Shares. This tranche of Series B Preferred Shares is convertible into 7,318,084 shares of common stock based on the current conversion price, at a purchase price of $0.325 per share. Net proceeds were approximately $1,772,500 after legal and placement agent fees and the satisfaction of the promissory notes.

On October 11, 2017, as contemplated by the Initial Series B Purchase Agreement, the Parties entered into a fifth Series B Preferred Stock Purchase Agreement (the “Fifth Series B Purchase Agreement”) whereby the Company issued and sold to accredited investors 231,097 shares of the Company’s Series B Preferred Stock in exchange for an aggregate cash payment equal to $75,000. Upon further review of the Fifth Series B Purchase Agreement, it was noted the total number of shares issued under the Fifth Series B Purchase Agreement was 462,195 shares with total proceeds of $150,000.

On October 31, 2017, as contemplated by the Initial Series B Purchase Agreement, the Parties entered into a sixth Series B Preferred Stock Purchase Agreement (the “Sixth Series B Purchase Agreement”) whereby the Company issued and sold to accredited investors 795,833 shares of the Company’s Series B Preferred Stock in exchange for an aggregate cash payment equal to $80,000. Upon further review of the Sixth Series B Purchase Agreement, it was noted the total number of shares issued under the Sixth Series B Purchase Agreement was 1,042,337 shares with total proceeds of $557,500.

As a result of the October 11, 2017 and October 31, 2017 transactions, the Company recorded an increase of $477, $552,023 and $552,500 to Series B Preferred Shares – par amount, additional paid-in capital and accumulated deficit, respectively.

On November 16, 2017, the Company amended Notes Five, Six, and Seven (“the Amended Notes”) with the Fourth Investor. All three notes shall have maturity dates that are six months from November 16, 2017, shall convert at a 40% discount to the lowest one-day Volume Average Weighted Price (“VWAP”) during the 30 trading days preceding such conversion, shall incur interest at an annual rate of 5%, and shall be prepayable at any time at 110% of the unpaid principal and accrued interest balances. The amendment of Note Six and Seven included terms, permitting the Company the option to tender payment in full on or before November 21, 2017, at a 15% discount of the amended principal amounts. Note Five, Six and Seven Principal Amounts were amended to $281,900, $38,441 and $131,107, respectively. The Company evaluated the Amended Notes in accordance with ASC 480, Distinguishing Liabilities from Equity and determined the Amended Notes will be accounted for as a liability initially measured at fair value and subsequently at fair value with changes in fair value recognized in earnings. At November 16, 2017, the principal amounts of Note Five, Six and Seven were $281,900, $38,441 and $131,107, respectively. As of December 31, 2017, the Company recorded the fair value of Note Five, Six and Seven at $812,393, $110,781 and $377,830, respectively. Therefore, the Company recorded a charge to the change in fair value of $(530,493), $(72,340) and $(246,723) related to Note Five, Six and Seven, respectively.

Upon further review it was noted, on November 21, 2017, the Company paid the remaining principal balance, at the 15% discount on Notes Six and Seven in the amount of $144,259. Therefore, Notes Six and Seven did not have a balance as of December 31, 2017.

As a result of the November 21, 2017 transaction, the Company recorded a reduction to convertible notes payable, net of discount of $488,611 and a credit to the change in fair value of convertible notes of $488,611.

When taking into consideration the two transactions indicated above, the net impact to accumulated deficit was a charge of $63,889, resulting from the netting of the gain of $488,611 from the reduction in the fair value of convertible notes at December 31, 2017 offset by the $552,500 of additional expense associated with the Series B Purchase Agreement.

Upon further review it was noted that, during the six months ended June 30, 2018 the Company erroneously recorded revenue for transactions with a consolidating entity and not recording the intercompany entry to eliminate the revenue. Therefore revenue and cost of revenues for the six months ended June 30, 2018 were overstated by $338,437. The Company will adjust for these errors on a prospective basis.

Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s amended audited consolidated financial statements for the year ended December 31, 2017 included in the Company’s Amended Fiscal 2017 Annual Report on Form 10-K/A, filed with the SEC on April 4, 2018. In addition, the Company’s future Quarterly Reports on Form 10-Q for subsequent quarterly periods during the current fiscal year will reflect the impact of the revision in the comparative prior quarter and year-to-date periods.

~~The following table summarizes the effects of the revisions on the financial statements for the periods reported.~~

Previously
Reported Adjustments Revised
Condensed Consolidated Balance Sheet as of December 31, 2017
Convertible notes payable, net of discount $ 1,301,004 $ (488,611 ) $ 812,393
Total liabilities $ 5,350,899 $ (488,611 ) $ 4,862,288
Preferred Shares (Class B) Outstanding 13,306,599 477,602 13,784,201
Preferred Shares (Class B) Par Amount $ 13,307 $ 477 $ 13,784
Additional Paid in Capital $ 3,923,234 $ 552,023 $ 4,475,257
Accumulated Deficit $ (18,177,819 ) $ (63,889 ) $ (18,241,708 )
Total Shareholders’ Equity $ 54,350 $ 488,611 $ 542,961
Total Liabilities and Shareholders’ Equity $ 5,405,249 $ - $ 5,405,249

Previously Reported Adjustments As revised
Condensed Consolidated Statement of Operations for the Six Months Ended June 30, 2018
Revenue $ 3,340,817 $ (338,437 ) $ 3,002,380
Cost of Revenue $ 2,689,529 $ (338,437 ) $ 2,351,092

3.	Going Concern Uncertainty, Financial Condition and Management’s Plans

The Company believes that there is substantial doubt about the Company’s ability to continue as a going concern. The Company believes that its available cash balance as of the date of this filing will not be sufficient to fund its anticipated level of operations for at least the next 12 months. The Company believes that its ability to continue operations depends on its ability to sustain and grow revenue and results of operations as well as its ability to access capital markets when necessary to accomplish the Company’s strategic objectives. The Company believes that it will continue to incur losses for the immediate future. The Company expects to finance future cash needs from its results of operations and, depending on the results of operations, the Company may need additional equity or debt financing until it can achieve profitability and positive cash flows from operating activities, if ever.

At ~~September~~June 30, ~~2018,~~2019, the Company had a working capital deficit of ~~approximately $2,287,082,~~$3,715,022, as compared to a working capital deficit of ~~approximately $3,289,281~~$2,233,652 at December 31, ~~2017.~~2018. The ~~decrease~~increase of ~~$1,002,199~~$1,481,370 in the Company’s working capital deficit from December 31, ~~2017~~2018 to ~~September~~June 30, ~~2018~~2019 was primarily the result of a ~~decrease~~non-cash increase in the ~~Company’s obligation to issue warrants and a decrease in the balance~~fair market value of the Company’s convertible notes payable, net of discount – related party and an increase in the warrant liability, partially offset by a decrease in ~~cash and increase in accounts payable and accrued liabilities.~~contingent consideration.

The Company’s future capital requirements for its operations will depend on many factors, including the profitability of its businesses, the number and cash requirements of other acquisition candidates that the Company pursues, and the costs of operations. The Company has been investing in expanding its operation in new states, its security service in Colorado and California, and upgrading the capabilities of BioTrackTHC. The Company’s management has taken several actions to ensure that it will have sufficient liquidity to meet its obligations ~~through December 31, 2018,~~for the next twelve months, including growing and diversifying its revenue streams, selectively reducing expenses, and considering additional funding. Additionally, if the Company’s actual revenues are less than forecasted, the Company anticipates that variable expenses will also decline, and the Company’s management can implement expense reduction as necessary. The Company is evaluating other measures to further improve its liquidity, including the sale of equity or debt securities. Lastly, the Company may elect to reduce certain related-party and third-party debt by converting such debt into common shares. The Company’s management believes that these actions will enable the Company to meet its liquidity requirements through ~~November 15, 2019.~~August 16, 2020. There is no assurance that the Company will be successful in any capital-raising efforts that it may undertake to fund operations during ~~2018~~2019 and beyond.

On May 31, 2019 the Company filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the securities being offered. The Company is working with an investment bank to identify investors in anticipation of raising up to $5 million in new equity capital.

The Company plans to generate positive cash flow from its Colorado and California security operations, BioTrackTHC and Engeni ~~acquisitions~~software operations to address some of the liquidity concerns. However, to execute the Company’s business plan, service existing indebtedness and implement its business strategy, the Company anticipates that it will need to obtain additional financing from time to time and may choose to raise additional funds through public or private equity or debt financings, borrowings from affiliates or other arrangements. The Company cannot be sure that any additional funding, if needed, will be available on terms favorable to the Company or at all. Furthermore, any additional capital raised through the sale of equity or equity-linked securities may dilute the Company’s current stockholders’ ownership and could also result in a decrease in the market price of the Company’s common stock. The terms of those securities issued by the Company in future capital transactions may be more favorable to new investors and may include the issuance of warrants or other derivative securities, which may have a further dilutive effect. The Company also may be required to recognize non-cash expenses in connection with certain securities it issues, such as convertible notes and warrants, which may adversely impact the Company’s operating results and financial condition. Furthermore, any debt financing, if available, may subject the Company to restrictive covenants and significant interest costs. There can be no assurance that the Company will be able to raise additional capital, when needed, to continue operations in their current form.

4.3.	Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, which include Helix TCS, LLC (“Helix TCS”), Security Consultants Group, LLC (“Security Consultants”), Boss Security Solutions, Inc. (“Boss Security”), Security Consultants Group Oregon, LLC (“Security Oregon”), Security Grade, BioTrackTHC (since June 1, ~~2018), and~~2018, Engeni US (since August 3, 2018), and Tan Security (since April 1, 2019).

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. ~~Use of~~Significant estimates ~~includes the following: 1)~~made by management include, but are not limited to allowance for doubtful accounts, ~~2) estimated~~purchase accounting allocations, recoverability and useful lives of property, equipment and intangible assets, ~~3) intangibles impairment, 4)~~ valuation of convertible notes payable, contingencies, warrant liabilities, equity compensation and 5) revenue recognition. Actual results could differ from estimates.

Cash

Cash consists of checking accounts. The Company considers all ~~highly-liquid~~highly liquid investments purchased with a maturity of three months or less at the time of purchase to be ~~cash.~~ cash equivalents. The Company has no cash equivalents as of June 30, 2019 or December 31, 2018.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are recorded at the invoiced amount, net of an allowance for doubtful accounts. The Company performs ongoing credit evaluations of its customers and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by the review of their current credit information; and determines the allowance for doubtful accounts based on historical write-off experience, customer specific facts and economic conditions.

Management charges balances off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company determines when receivables are past due, or delinquent based on how recently payments have been received.

Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Allowance for doubtful accounts was ~~$65,103~~$77,046 and ~~$3,000~~$76,156 at ~~September~~June 30, ~~2018~~2019 and December 31, ~~2017,~~2018, respectively.

Long-Lived Assets, Including Definite Lived Intangible Assets

Long-lived assets, other than goodwill and other indefinite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows derived from such assets. Definite-lived intangible assets primarily consist of non-compete agreements and customer relationships. For long-lived assets used in operations, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.

Goodwill

Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value-based test. Helix reviews goodwill for possible impairment annually during the fourth quarter, or whenever events or circumstances indicate that the carrying amount may not be recoverable.

The impairment model prescribes a two-step method for determining goodwill impairment. However, an entity is permitted to first assess qualitative factors to determine whether the two-step goodwill impairment test is necessary. The qualitative factors considered by Helix may include, but are not limited to, general economic conditions, Helix’s outlook, market performance of Helix’s industry and recent and forecasted financial performance. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. In the first step, Helix determines the fair value of its reporting unit using a discounted cash flow analysis. If the net book value of the reporting unit exceeds its fair value, Helix then performs the second step of the impairment test, which requires allocation of the reporting unit’s fair value to all of its assets and liabilities using the acquisition method prescribed under authoritative guidance for business combinations with any residual fair value being allocated to goodwill. An impairment charge is recognized when the implied fair value of Helix’s goodwill is less than its carrying amount.

Assumptions and estimates used in the evaluation of impairment may affect the carrying value of long-lived assets, which could result in impairment charges in future periods. Such assumptions include projections of future cash flows and the current fair value of the asset. It was determined that during the first quarter of 2018, the Company’s entire amount of goodwill attributable to the Security Grade acquisition was impaired. See Note 9 for a further discussion on the impairment.asset

Accounting for Acquisitions

In accordance with the guidance for business combinations, the Company determines whether a transaction or other event is a business combination, which requires that the assets acquired, and liabilities assumed constitute a business. Each business combination is then accounted for by applying the acquisition method. If the assets acquired are not a business, the Company accounts for the transaction or other event as an asset acquisition. Under both methods, the Company recognizes the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquired entity. In addition, for transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase. The Company capitalizes acquisition-related costs and fees associated with asset acquisitions and immediately ~~expense~~expenses acquisition-related costs and fees associated with business combinations.

~~Business Combinations~~

The Company accounts for its business combinations under the provisions of Accounting Standards Codification (“ASC”) Topic 805-10,Business Combinations (“(“ASC 805-10”), which requires that the purchase method of accounting be used for all business combinations. Assets acquired and liabilities assumed, including non-controlling interests, are recorded at the date of acquisition at their respective fair values. ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in fair value after the acquisition date are accounted for as measurement-period adjustments. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings.

The estimated fair value of net assets acquired, including the allocation of the fair value to identifiable assets and liabilities, was determined using established valuation techniques. The estimated fair value of the net assets acquired was determined using the income approach to valuation based on the discounted cash flow method. Under this method, expected future cash flows of the business on a stand-alone basis are discounted back to a present value. The estimated fair value of identifiable intangible assets, consisting of software and trade name acquired were determined using the relief from royalty method.

The most significant assumptions under the relief from royalty method used to value software and trade names include: estimated remaining useful life, expected revenue, royalty rate, tax rate, discount rate and tax amortization benefit. The discounted cash flow method used to value non-compete agreements includes assumptions such as: expected revenue, term of the non-compete agreements, probability and ability to compete, operating margin, tax rate and discount rate. Management has developed these assumptions on the basis of historical knowledge of the business and projected financial information of the Company. These assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management, and such variations may be significant to estimated values.

Revenue Recognition

Under ~~FASB~~Financial Accounting Standards Board (“FASB”) Topic 606, Revenue from Contacts with Customers (“ASC 606”), the Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which is expected to be received in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenues when (or as) the Company satisfies a performance obligation.

The security services revenue is generated from performing armed and unarmed guarding which is contracted for on an hourly basis. Revenues associated with these contracted services are recognized under time-based arrangements as services are provided.

Additionally, the Company provides transportation security services, which are generally contracted for on a per-run basis and sometimes additional fees and surcharges are also billed to the client depending on the length of the run. Revenues associated with these services are recognized as the transportation service is provided.

The Company also generates revenue from developing and licensing seed to sale cannabis compliance software to both private-sector and public-sector (government agencies) businesses that are involved in cannabis related operations. The Company also generates revenue from on-going training, support and software customization services.

Occasionally, the Company will enter into systems installation arrangements. Installation jobs are estimated based on the cost of equipment to be installed, the number of hours expected to be incurred to complete the job and other ancillary costs. Revenue associated with these services are recognized over the arrangement period.

Lastly, the Company generates advertising revenues from consumer advertising on its Cannabase platform. Revenue is recognized over the contract period associated with each specific advertising campaign.

Segment Information

~~Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”)~~FASB ASC Topic 280, Segment Reporting, establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is the Chief Executive Officer, who reviews the financial performance and the results of operations of the segments prepared in accordance with GAAP when making decisions about allocating resources and assessing performance of the Company.

Asset information by operating segment is not presented since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company’s condensed unaudited consolidated financial statements.

Expenses

Cost of Revenues

The cost of revenues is the total cost incurred to obtain a sale and the cost of the goods or services sold. Cost of revenues primarily consisted of hourly compensation for security personnel and employees involved in the creation and development of licensing software.

Operating Expenses

Operating expenses encompass selling general and administrative expenses, salaries and wages, professional and legal fees, depreciation and ~~depreciation.~~amortization, and loss on impairment of Goodwill. Selling, general and administrative expenses consist primarily of rent/moving expenses, advertising and travel expenses. Salaries and wages is composed of non-revenue generating employees. Professional services are principally comprised of outside legal, audit, information technology consulting, marketing and outsourcing services as well as the costs related to being a publicly traded company.

Other ~~(Expense)~~ Income (Expense), net

Other income (expense) ~~income,~~, net consisted of change in fair value of convertible note, change in fair value of convertible note – related party, ~~interest expense,~~ change in fair value of ~~obligation to issue warrants,~~contingent consideration, change in fair value of warrant liability, loss on ~~extinguishment~~issuance of ~~debt, loss on impairment of Goodwill and~~warrants, gain on reduction of obligation pursuant to ~~acquisition.~~ acquisition and interest (expense) income.

Property and Equipment

Property and equipment are stated at cost and depreciated on a straight-line basis over their estimated useful lives. Useful lives are 3 years for vehicles and 5 years for furniture and equipment. Maintenance and repairs are expensed as incurred and major improvements are capitalized. When assets are sold, or retired, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is included in other income.

Contingencies

Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.

~~Leases~~

Lease agreements are evaluated to determine if they are capital leases meeting any of the following criteria at inception: (a) transfer of ownership; (b) bargain purchase option; (c) the lease term is equal to 75 percent or more of the estimated economic life of the leased property; or (d) the present value at the beginning of the lease term of the minimum lease payments, excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, including any profit thereon, equals or exceeds 90 percent of the excess of the fair value of the leased property to the lessor at lease inception over any related investment tax credit retained by the lessor and expected to be realized by the lessor.

If at its inception, a lease meets any of the four lease criteria above, the lease is classified by the Company as a capital lease; and if none of the four criteria are met, the lease is classified by the Company as an operating lease.

Operating lease payments are recognized as an expense in the income statement on a straight-line basis over the lease term, whereby an equal amount of rent expense is attributed to each period during the term of the lease, regardless of when actual payments are made. This generally results in rent expense in excess of cash payments during the early years of a lease and rent expense less than cash payments in the later years. The difference between rent expense recognized and actual rental payments is recorded as deferred rent and included in liabilities.

Advertising

Advertising costs are expensed as incurred and included in selling, general and administrative expenses and amounted to ~~$9,079~~$178,219 and ~~$7,298~~$34,963 for the three months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, respectively, and ~~$74,408~~$247,490 and ~~$12,477~~$61,737 for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, respectively.

Foreign Currency

The local currency is the functional currency for one entity’s operations outside the United States. Assets and liabilities of these operations are translated to U.S. dollars at the exchange rate in effect at the end of each period. Income statement accounts are translated at the average exchange rate prevailing during the period. Translation adjustments arising from the use of differing exchange rates from period to period are included as a component of other comprehensive ~~loss~~income within shareholders’ equity. Gains and losses from foreign currency transactions are included in net loss for the period.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has incurred net operating loss for financial-reporting and tax-reporting purposes. Accordingly, for Federal and state income tax purposes, the benefit for income taxes has been offset entirely by a valuation allowance against the related federal and state deferred tax asset for the nine months ended September 30, 2018 and 2017.

Comprehensive ~~Loss~~Income (Loss)

Comprehensive ~~loss~~income (loss) consists of consolidated net ~~loss~~income (loss) and foreign currency translation adjustments. Foreign currency translation adjustments included in comprehensive ~~loss~~income (loss) were not tax-effected as investments in international affiliates are deemed to be permanent.

Distinguishing Liabilities from Equity

The Company relies on the guidance provided by ASC Topic 480, Distinguishing Liabilities from Equity, to classify certain redeemable and/or convertible instruments. The Company first determines whether a financial instrument should be classified as a liability. The Company will determine the liability classification if the financial instrument is mandatorily redeemable, or if the financial instrument, other than outstanding shares, embodies a conditional obligation that the Company must or may settle by issuing a variable number of its equity shares.

Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity.

Initial Measurement

The Company records its financial instruments classified as liability, temporary equity or permanent equity at issuance at the fair value, or cash received.

Subsequent Measurement – Financial instruments classified as liabilities

The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in fair value of its financial instruments classified as liabilities are recorded as other expense/income.

Beneficial Conversion Feature

If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value, this feature is characterized as a Beneficial Conversion Feature (“BCF”). A beneficial conversion feature is recorded by the Company as a debt discount pursuant to ASC 470-20,Debt with Conversion and Other Options. In those circumstances, the convertible debt is recorded net of the discount related to the beneficial conversion feature and the Company amortizes the discount to interest expense over the life of the debt.

The Company accounts for the beneficial conversion feature on its convertible preferred stock in accordance with ASC 470-20,Debt with Conversion and Other Options. The BCF of convertible preferred stock is normally characterized as the convertible portion or feature that provides a rate of conversion that is below market value or in-the-money when issued. The Company records a BCF related to the issuance of convertible preferred stock when issued. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded when the contingency is resolved.

To determine the effective conversion price, the Company first allocates the proceeds received to the convertible preferred stock and then uses those allocated proceeds to determine the effective conversion price. If the convertible instrument is issued in a basket transaction (i.e., issued along with other freestanding financial instruments), the proceeds should first be allocated to the various instruments in the basket. Any amounts paid to the investor when the transaction is consummated (e.g., origination fees, due diligence costs) represent a reduction in the proceeds received by the issuer. The intrinsic value of the conversion option should be measured using the effective conversion price for the convertible preferred stock on the proceeds allocated to that instrument. The effective conversion price represents proceeds allocable to the convertible preferred stock divided by the number of shares into which it is convertible. The effective conversion price is then compared to the per share fair value of the underlying shares on the commitment date.

The accounting for a BCF requires that the BCF be recognized by allocating the intrinsic value of the conversion option to additional paid-in capital, resulting in a discount on the convertible preferred stock. This discount should be accreted from the date on which the BCF is first recognized through the earliest conversion date for instruments that do not have a stated redemption date. The intrinsic value of the BCF is recognized as a deemed dividend on convertible preferred stock over a period specified in the guidance.

Share-based Compensation

The Company accounts for stock-based compensation to employees in conformity with the provisions of ASC Topic 718,Stock Based Compensation. Stock-based compensation to employees consist of stock options grants and restricted shares that are recognized in the statement of operations based on their fair values at the date of grant.

~~The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 505, subtopic 50,~~~~Equity-Based Payments to Non-Employees~~ ~~based upon the fair-value of the underlying instrument. The equity instruments, are valued using the Black-Scholes valuation model.~~ The measurement of stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the period which services are received.

The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model and estimates the fair value of the stock based upon the estimated fair value of the common stock. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.

The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight- line basis over the requisite service period of the award.

Fair Value of Financial Instruments

ASC Topic 820,Fair Value Measurements and Disclosures (“ASC Topic 820”) provides a framework for measuring fair value in accordance with generally accepted accounting principles.

ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).

The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows:

	●	Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.

	●	Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

	●	Level 3 – Inputs that are unobservable for the asset or liability.

Certain assets and liabilities of the Company are required to be recorded at fair value either on a recurring or non-recurring basis. Fair value is determined based on the price that would be received for an asset or paid to transfer a liability in an orderly transaction based on market participants. The following section describes the valuation methodologies that the Company used to measure, for disclosure purposes, its financial instruments at fair value.

Convertible notes payable

The fair value of the Company’s convertible notes payable, approximated the carrying value as of ~~September~~June 30, ~~2018~~2019 and December 31, ~~2017.~~2018. Factors that the Company considered when estimating the fair value of its debt included market conditions and the term of the debt. The level of the debt would be considered as Level 2.

Warrant liabilities

The fair value of the Company’s warrant liabilities approximated the carrying value as of June 30, 2019 and December 31, 2018. Factors that the Company considered when estimating the fair value of its warrants included market conditions and the term of the warrants. The level of the warrant liabilities would be considered as Level 3.

Additional Disclosures Regarding Fair Value Measurements

The carrying value of cash, accounts receivable, prepaid expenses and other current assets, deposits and other assets, accounts payable and accrued liabilities, advances from ~~shareholders~~related parties and obligation pursuant to acquisition approximate their fair value due to the short-term maturity of those items.

Earnings (Loss) per Share

The Company follows ASC 260, Earnings Per Share, which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the income statement for all entities with complex capital ~~structures and requires a reconciliation of the numerator and denominator of the basic~~structures. Basic EPS ~~computation to the numerator and denominator of the diluted EPS computation. In the accompanying financial statements, basic earnings (loss) per share~~ is computed by dividing net ~~loss~~income (loss) available to common shareholders (numerator) by the weighted average number of shares ~~of common stock~~ outstanding (denominator) during the period. Diluted EPS ~~excluded~~gives effect to all dilutive potential ~~dilutive~~common shares ~~if their effect was anti-dilutive.~~outstanding during the period including stock options and warrants, using the treasury stock method, and convertible debt and convertible securities, using the if-converted method.

~~Basic net loss per share is based on~~For the ~~weighted average number of common~~three months ended June 30, 2018 and ~~common-equivalent shares outstanding. Potential~~the six months ended June 30, 2019 and 2018, potential common shares includable in the computation of fully-diluted per share results are not presented in the condensed consolidated financial statements ~~for the three and nine months ended September 30, 2018 and 2017~~ as their effect would be anti-dilutive. For the three months ended June 30, 2019, dilutive earnings per share are calculated by dividing net income attributable to common shareholders less the change in fair value of warrant liability, the change in fair value of convertible notes, interest expense on convertible notes, and the debt discount amortized on convertible notes. The calculation of diluted EPS excludes 24,571,582 shares for securities which have been deemed to be anti-dilutive.

~~Basic loss per common share is computed based on the weighted average number of shares outstanding during the period. Diluted loss~~Earnings per share ~~is computed in a manner similar to~~for the basic loss per share, except the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of warrants, options, convertible debtthree and other such convertible instruments. Diluted loss per share contemplates a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share.six months ended June 30, 2019 and 2018 were calculated as follows:

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2019			2018			2019			2018
Numerator
Net income attributable to common shareholders	$	4,811,718		$	(9,032,037	)	$	(6,025,736	)	$	(24,469,219	)
Effect of dilutive instruments on net loss		(7,024,580	)		-			-			-
Net income (loss) attributable to common shareholders - diluted	$	(2,212,862	)	$	(9,032,037	)	$	(6,025,736	)	$	(24,469,219	)

Denominator
Weighted average shares of common stock outstanding - basic		75,470,238			42,673,528			74,324,689			35,907,118

Dilutive effect of warrants and convertible securities		5,766,440			-			-			-

Weighted average shares of common stock outstanding - diluted		81,236,678			42,673,528			74,324,689			35,907,118

Net income (loss) per share
Basic	$	0.06		$	(0.21	)	$	(0.08	)	$	(0.68	)
Diluted	$	(0.03	)	$	(0.21	)	$	(0.08	)	$	(0.68	)

The anti-dilutive shares of common stock outstanding for the three and ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018 were as follows:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,				For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2018		2017		2018		2017		2019		2018		2019		2018
Potentially dilutive securities:
Convertible notes payable		106,957		226,320		106,957		226,320		-		135,634		2,704,577		135,634
Convertible Preferred A Stock		1,000,000		1,000,000		1,000,000		1,000,000		1,000,000		1,000,000		1,000,000		1,000,000
Convertible Preferred B Stock		13,784,201		9,830,035		13,784,201		9,830,035		13,784,201		13,784,201		13,784,201		13,784,201
Warrants		3,307,073		2,557,195		3,307,073		2,557,195		-		3,307,073		4,925,558		3,307,073
Stock options		8,739,669		-		8,739,669		-		9,787,381		8,704,345		9,787,381		8,704,345

Reclassifications

Certain reclassifications have been made to the prior period financial statements to conform to the current period financial statement presentation. These reclassifications had no effect on net earnings or cash flows as previously reported.

Recent Accounting Pronouncements

~~In May 2014, the FASB issued ASU 2014-09,~~~~“Revenue from Contracts with Customers” (“ASU 2014-09”).~~The objective of ASU 2014-09 is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most of the existing revenue recognition guidance, including industry specific guidance. The core principle of ASU 2014-09 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the new guidance, an entity will: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the contract’s performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 applies to all contracts with customers except those that are within the scope of other topics in the FASB ASC. In April and May 2016, the FASB issued ASU 2016-10,~~“Revenue from Contracts with Customers – Identifying Performance Obligations and Licensing”~~~~, ASU 2016-11,~~~~“Revenue Recognition and Derivatives and Hedging – Recession of SEC Guidance”,~~ ~~ASU 2016-12~~~~, “Revenue from Contracts with Customers – Narrow-Scope Improvements and Practical Expedients”,~~ ~~and ASU 2016-20~~~~, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers”.~~ These ASUs each affect the guidance of the new revenue recognition standard in ASU 2014-09 and related subsequent ASUs. The new guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2017 for public companies

~~On January 1, 2018, we adopted the new accounting standard ASC 606~~~~, “Revenue from Contracts with Customers~~ and all the related amendments” (“ASC 606”) to all contracts which were not completed or expired as of January 1, 2018 using the modified retrospective method. The Company had no cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while the comparative information will continue to be reported under the accounting standards in effect for those periods.

In February 2016, the FASB issued ASU ~~2016-02,~~ 2016-.02,~~“Leases”,~~ which is effective for public entities for annual reporting periods beginning after December 15, 2018. Under ASU 2016-02, lessees will be required to recognize the following for all leases (with the exception of leases with terms of less than one year) at the commencement date: 1) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and 2) a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to ASC 842 (Leases), and ASU 2018-11, Leases (Topic 842)~~: Targeted Improvements,~~ (“Topic 842”) which ~~provide (i) narrow amendments to clarify how to apply certain aspects~~requires the recognition of right-of-use assets and lease liabilities on the balance sheet. The most prominent of the ~~new~~changes in the standard is the recognition of right-of-use (“ROU”) assets and lease ~~standard, (ii) entities with an additional (and optional) transition method to adopt the new~~liabilities by lessees for those leases standard, and (iii) lessors with a practical expedient for separating components of a contract. All ASUs are effective for annual periods and interim periods within those annual periods beginning after December 31, 2018. The Company is still evaluating the method of adoption. While the Company is continuing to assess all potential impacts of the new standard, the Company currently believes the most significant impact relates to its accounting for office space, colocationclassified as operating ~~leases, and embedded leases within its supplier contracts.~~leases.

~~In January 2017, the FASB issued ASU 2017-01,~~~~Business Combinations (Topic 805) Clarifying the Definition of a Business.~~The amendments in this Update is to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company adopted ~~this~~the new standard on January 1, ~~2018.~~2019 and used the modified retrospective approach with the effective date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company elected certain practical expedients, which among other things, allowed us to carry forward prior conclusions about lease identification and classification.

~~In January 2017, the FASB issued ASU No. 2017-04,~~~~Intangibles – Goodwill and Other (Topic 350); Simplifying the Test for Goodwill Impairment.~~ The amendments in this update simplify the measurement of goodwill by eliminating Step 2 from the goodwill impairment test. Under this guidance, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss should not exceed the total amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for public companies for the reporting periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. Accordingly, at March 31, 2018, goodwill was tested for potential impairment. As a resultAdoption of the ~~goodwill impairment test performed, it was determined that~~standard resulted in the ~~carrying value~~balance sheet recognition of additional lease assets and lease liabilities of approximately $1,500,000. The new standard also provides practical expedients for ~~each reporting unit was higher than its fair value. Please refer to FN 9 for further detail.~~

~~In May 2017,~~an entity’s ongoing accounting. The Company currently has elected the ~~FASB issued ASU No 2017-09~~~~“Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting”~~(ASU 2017-09). ASU 2017-09 provides clarity and reduces both (i) diversity in practice and (ii) cost and complexity when applying the guidance in Topic 718, Compensation-Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. An entity should account for the effects of a modification unless all three of the following are met: (1) The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification. (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified. (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. Note that the current disclosure requirements in Topic 718 apply regardless of whether an entity is required to apply modification accounting under the amendments in ASU 2017-09. ASU 2017-09 is effectiveshort-term lease recognition exemption for all ~~annual periods, and interim periods within~~leases that qualify. This means, for those ~~annual periods, beginning after December 15, 2017. The updated standard was adopted by~~leases that qualify, the Company ~~on January 1, 2018. The adoption~~will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of ~~this accounting standard did not have a material impact on~~those assets in separate lease and non-lease components for all our leases. For additional information regarding the Company’s leases, see Note 18 in the notes to condensed consolidated financial statements.

In July 2017, the FASB issued ASU 2017-11,Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope ~~Exception.~~Exception. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company ~~is currently assessing~~adopted this ASU as of January 1, 2019. The amendments in this ASU did not have a material impact on the ~~potential impact of adopting ASU 2017-11 on its~~Company’s consolidated financial ~~statements and related disclosures.~~statements.

In February 2018, the FASB issued ASU 2018-02,Income Statement – Reporting Comprehensive Income (Topic 220); Reclassification of Certain Tax Effects from Accumulated Other Comprehensive ~~Income.~~Income. The amendments in this ASU allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. Consequently, the amendments eliminate the stranded tax effects resulting from the Act and will improve the usefulness of information reported to financial statement users. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted in any interim period after issuance of the ASU. The Company ~~is evaluating~~adopted this ASU as of January 1, 2019. The amendments in this ASU did not have a material impact on the ~~effect that this update will have on its~~Company’s consolidated financial ~~statements and related disclosures.~~statements.

In June 2018, the FASB issued ASU 2018-07,Compensation-Stock Compensation (ASC 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of ASC 718 to include share-based payment transactions for acquiring goods and services from nonemployees and applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. ASC 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. This update is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. ~~Early adoption is permitted, but no earlier than an entity’s adoption date of ASC 606.~~ The Company ~~is evaluating~~adopted this ASU as of January 1, 2019. The amendments in this ASU did not have a material impact on the ~~effect that this update will have on its~~Company’s consolidated financial ~~statements and related disclosures.~~statements.

In August 2018, the FASB issued ASU 2018-13,Fair Value Measurement (ASC 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 removes certain disclosures, modifies certain disclosures and adds additional disclosures. The ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2019. Early adoption is permitted. The Company is evaluating the effect that this update will have on its financial statements and related disclosures.

Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on ~~our~~the Company’s consolidated financial statements and related disclosures.

5.4.	Revenue Recognition

~~Adoption of ASC 606 Revenue from Contracts with Customers~~

The Company adopted the new revenue standard, ASC 606, using the modified retrospective method with respect to all non-completed contracts as of January 1, 2018. This method required retrospective application of the new accounting standard to all unfulfilled contracts that were outstanding as of January 1, 2018. Revenues and contract assets and liabilities for contracts completed prior to January 1, 2018 are presented in accordance with ASC 605.

~~The Company has determined that there were no adjustments required with respect to the adoption of ASC 606 with respect to any prior periods.~~

Disaggregation of revenue

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,				For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2018		2017		2018		2017		2019		2018		2019		2018
Types of Revenues:
Security and Guarding	$	1,141,676	$	1,129,746	$	3,432,651	$	2,837,145	$	1,347,529	$	1,197,201	$	2,552,240	$	2,290,975
Systems Installation		318,850		-		454,113		-		174,067		100,699		202,608		135,263
Software		1,653,195		-		2,229,337		-		2,377,277		576,142		4,515,132		576,142
Total revenues	$	3,113,721	$	1,129,746	$	6,116,101	$	2,837,145	$	3,898,873	$	1,874,042	$	7,269,980	$	3,002,380

The following is a description of the principal activities from which we generate our revenue.

Security and Guarding Revenue

Helix provides armed and unarmed guards, monitoring of security alarms and cameras, as well as armed transportation services. The guards are charged out at an hourly rate, as are the monitoring services, with invoices typically sent to clients shortly after each month-end for the previous month, with revenue being recognized ~~at a point in time once~~over time. The customer simultaneously receives and consumes benefits provided by the ~~service has been provided.~~Helix performance. Transportation services are typically invoiced on a per-run basis, with revenue being recognized at a point in time once the service has been completed.

Systems Installation Revenue

Security systems, including ~~IP CCTV,~~Internet Protocol camera, intrusion alarm systems, perimeter alarm systems, and access controls are installed for clients. Installation jobs are estimated based on the cost of the equipment, the number of man hours expected to complete the work, supplies, travel, and any other ancillary costs. The installation is typically invoiced with 60% of the total price immediately after signing and the balance upon completion of the installation service. The timing of these contracts are short-term in nature and are less than 12 months in ~~duration.~~duration, and revenue is recognized over the term of the contracts, utilizing the cost-to-cost method.

Software

The Company generates revenue from developing and licensing seed to sale cannabis compliance software to both private-sector and public-sector (government agencies) clients that are involved in cannabis related operations. The Company also generates revenue from on-going training, support and software customization services.

The private-sector software entails cultivation tracking, inventory management, point of sale and analytic reporting to assist businesses in meeting their compliance requirements and effectively managing their businesses. Customers within the private sector business are charged an initial one-time installation fee and the revenues associated with these services are recognized upon completion of installation and configuration at a point in time. After the installation and configuration of the software is completed, the customer is invoiced monthly and revenues associated with these services are recognized monthly over a period of time in which the customer continues to use the software and related services.

The public-sector software assists government agencies in efficient oversight of cannabis related business under their jurisdiction. Revenues associated with governmental contracts are longer-term in nature and recognized upon completion of certain milestones over a period of time or on a completed-contract basis at a point in time. The Company considers the contract to be complete when all significant costs have been incurred and the customer accepts the project. Costs incurred prior to the customer accepting the project are deferred and reflected on the ~~Balance Sheet~~condensed consolidated balance sheets as ~~Work-in-process – Traceability.~~prepaid expenses and other current assets.

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in accordance with ASC 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Generally, the Company’s contracts include a single performance obligation that is separately identifiable, and therefore, distinct. Under ASC 606, the allocation of transaction price is not necessary if only one performance obligation is identified.

Significant Judgments

Accounting for long-term contracts involves the use of various techniques to estimate total contract revenue, costs and satisfaction of performance obligation. The Company satisfies its performance obligations and subsequently recognizes revenue, ~~at a point in~~over time, as security and installation services are performed. There were no changes to the significant judgments used by the Company to determine the timing of satisfaction of the performance obligations under ASC 606.

Costs to Obtain or Fulfill Contract

The Company’s costs to fulfill or obtain contracts with customers primarily consist of commissions and legal costs. The Company provides sales team members with commissions at 0-6%. Although sales commissions are incremental in nature and are only incurred when a contract is obtained, there is no up-front commission paid on the satisfactory obtainment of a contract, resulting in no sales commissions being capitalized at ~~September~~June 30, 2019 and December 31, 2018. The Company also incurs legal costs relating to the drafting and negotiating of contracts with select customers. Because legal costs are not incremental in nature and are incurred regardless of whether a contract is ultimately obtained, there were no legal costs capitalized as of ~~September~~June 30, 2019 and December 31, 2018. The Company did not record amortization of costs incurred to obtain the contract or any impairment losses for the period ending ~~September~~June 30, 2019 and 2018.

6.5.	Business Combinations

Security Grade Acquisition

On June 2, 2017 (the ~~“Closing”~~“Security Grade Closing Date”), the Company entered into a Membership Interest Purchase Agreement (the ~~“Agreement”~~“Security Grade Acquisition Agreement”) in which the Company purchased all issued and outstanding ~~Units~~units of Security Grade Protective Services, Ltd. (“Security Grade”), which ~~comprised~~consisted of 800,000 Class A Units and 200,000 Class B Units. ~~At closing,~~On the Security Grade Closing Date, the Company delivered $800,000 in cash and 207,427 non-qualified stock options (the “Initial Stock Options”). Furthermore, provided that, within the first 60 days following the ~~closing,~~Security Grade Closing Date, no material customer identified in the Security Grade Acquisition Agreement terminates its contractual relationship with the Company and that all contracts with such material customers are in full force and effect without default or cancellation as of the 60^th60th day following the ~~closing,~~Security Grade Closing Date, on the 61^st61st day following the ~~closing,~~Security Grade Closing Date, the Company shall ~~deliver~~issue an additional $800,000 in cash and issue 207,427 additional stock options (the “Additional Stock Options”). In the event of termination, cancellation or default of any contract with one or more material customer identified in the Security Grade Acquisition Agreement within the first 60 days following the ~~closing,~~Security Grade Closing Date, the stock options received by the acquiree shall be reduced and/or forfeited to the extent necessary (pro rata based upon their ownership interest in the Company immediately preceding the closing) by a percentage equal to the revenue received by the Company from the terminating customer(s) in the 180 days immediately preceding such termination divided by the revenue received by the Company from all material customers identified in the Security Grade Acquisition Agreement in the 180 days immediately preceding such termination. The Company subsequently issued the 207,427 Additional Stock Options on August 1, 2017 as well as a second cash payment of $800,000 pursuant to the original terms of the Security Grade Acquisition Agreement.

In the first quarter of 2018, the Company notified the selling members of Security Grade of their intent to exercise their right of setoff noted in the Security Grade Acquisition Agreement after discovering misrepresentations made by one of the selling members of Security Grade. The Company has settled with all of the six selling members. As of ~~September~~June 30, 2019 and December 31, 2018, the Company has a liability pursuant to the Security Grade Acquisition Agreement of ~~$153,333~~$0 and $101,667, respectively, payable following the ~~Closing.~~

closing.

The merger is being accounted for as a business combination in accordance with ASC 805. The Company’s allocation of the purchase price was calculated as follows:

Base Price – Cash	$	2,100,373
Base Price - Stock Options		916,643
Contingent Consideration - Stock Options		916,643
Total Purchase Price	$	3,933,659

			Weighted Average Useful Life			Weighted Average Useful Life
Description	Fair Value		(in years)	Fair Value		(in years)
Assets acquired:
Cash	$	14,137		$	14,137
Accounts receivable		53,792			53,792
Costs & earnings in excess of billings		96,898			96,898
Property, plant and equipment, net		27,775			27,775
Trademarks		25,000	10		25,000	10
Customer lists		3,154,578	5		3,154,578	5
Web address		5,000	5		5,000	5
Goodwill		664,329			664,329
Other assets		3,880			3,880
Total assets acquired	$	4,045,389		$	4,045,389
Liabilities assumed:
Billings in excess of costs	$	23,967		$	23,967
Loans payable		18,414			18,414
Credit card payable and other liabilities		69,349			69,349
Total liabilities assumed		111,730			111,730
Estimated fair value of net assets acquired	$	3,933,659		$	3,933,659

The ~~initial stock options~~Initial Stock Options are included as part of the purchase price. The Company determined the fair value of the contingent consideration to be $916,643 at June 2, 2017 and recorded it as a liability in its unaudited condensed consolidated balance ~~sheets.~~sheet. The Company satisfied their contingent consideration liability during the third quarter of 2017. During the ~~period~~year ended ~~September 30,~~December 31, 2018, the Company reached settlement agreements with all six selling members. As a result of these settlements, ~~80,979~~79,486 options previously issued as part of the acquisition were ~~cancelled.~~cancelled (see Note 14).

~~BioTrack~~BioTrackTHC Acquisition

On March 3, 2018, ~~Helix TCS, Inc. (the “Company”)~~the Company and its wholly owned subsidiary, ~~Helix Acquisition~~Merger Sub, ~~Inc. (“Merger Sub”),~~ entered into anthe Merger Agreement ~~and Plan of Merger (the “Merger Agreement”)~~ with ~~Bio-Tech Medical Software, Inc. (“BioTrackTHC”)~~BioTrackTHC and Terence J. Ferraro, as the representative of the BioTrackTHC ~~shareholders. Pursuant~~shareholders, pursuant to ~~the Merger Agreement, subject to the satisfaction or waiver of specified conditions,~~which Merger Sub ~~will merge~~merged with and into BioTrackTHC. On the BioTrackTHC ~~with BioTrackTHC surviving the merger as a wholly-owned subsidiary of the Company (the “Merger”). On June 1, 2018,~~Closing Date, the Company closed the Merger. In connection with closing the Merger, the Company issued 38,184,985 unregistered shares of Company common stock to BioTrackTHC stockholders, of which 1,852,677 shares were held back to satisfy indemnification obligations in the Merger Agreement, if necessary. The Company also assumed the ~~Bio-Tech Medical Software, Inc 2014 Stock Incentive Plan (“~~BioTrackTHC Stock ~~Plan”),~~Plan, pursuant to which options exercisable for 8,132,410 shares of Company common stock are outstanding so that the BioTrackTHC stockholders will own 48% of the Company on a fully diluted ~~basis.~~basis at closing.

The Merger is being accounted for as a business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed in the BioTrackTHC merger. These values are subject to change as we perform additional reviews of our assumptions utilized.

~~The Company has made a provisional~~Company’s allocation of the purchase price ~~of the BioTrackTHC transaction to the assets acquired and the liabilities assumed~~was calculated as ~~of the purchase date. The following table summarizes the provisional purchase price allocations relating to the BioTrackTHC transaction:~~ follows:

Base Price - Common Stock	$	44,905,542
Base Price - Stock Options		12,646,491
Total Purchase Price	$	57,552,033

Weighted Average Useful Life
Description Fair Value (in years)
Assets acquired:
Cash $ 448,697
Accounts receivable 128,427
Prepaid expenses 351,615
Property, plant and equipment, net 72,252
Goodwill 39,135,007
Customer list 8,304,449 5
Software 9,321,627 4.5
Tradename 466,081 4.5
Total assets acquired $ 58,228,155
Liabilities assumed:
Accounts payable $ 223,581
Other liabilities 452,541
Total liabilities assumed 676,122
Estimated fair value of net assets acquired $ 57,552,033

The Company has not completed the valuation studies necessary to finalize the acquisition fair values of the assets acquired and liabilities assumed and related allocation of purchase price for BioTrackTHC. Accordingly, the type and value of the intangible assets amounts set forth above are preliminary. Once the valuation process is finalized for BioTrackTHC, there could be changes to the reported values of the assets acquired and liabilities assumed, including goodwill and intangible assets and those changes could differ materially from what is presented above.

Total acquisition costs for the BioTrackTHC merger incurred during the three and nine months ended September 30, 2018 was $116,624, and is included in selling, general and administrative expense in the Company’s Statements of Operations.

~~Unaudited Pro Forma Results~~

BioTrackTHC contributed revenues of $2,204,411 and a net loss of $(490,459) for the period June 1, 2018 through September 30, 2018, included in the Company’s consolidated condensed statements of operations.

The following table below represents the revenue, net loss and loss per share effect of the acquired company, as reported in our pro forma basis as if the acquisition occurred on January 1, 2017. These pro forma results are not necessarily indicative of the results that actually would have occurred if the acquisition had occurred on the first day of the periods presented, nor does the pro forma financial information purport to represent the results of operations for future periods.

For the Three Months Ended
September 30, For the Nine Months Ended
September 30,
Description 2018 2017 2018 2017
Revenues $ 3,134,396 $ 3,883,759 $ 8,957,690 $ 8,958,725
Net loss (2,722,404 ) 343,718 (5,213,028 ) (7,911,500 )
Net loss attributable to common shareholders (2,704,866 ) (7,701,240 ) (27,397,684 ) (19,320,872 )
Loss per share attributable to common shareholders:
Basic and diluted-as pro forma (unaudited) (0.04 ) (0.29 ) (0.57 ) (0.68 )

			Weighted Average Useful Life
Description	Fair Value		(in years)
Assets acquired:
Cash	$	448,697
Accounts receivable		128,427
Prepaid expenses		351,615
Property, plant and equipment, net		72,252
Goodwill		39,135,007
Customer list		8,304,449	5
Software		9,321,627	4.5
Tradename		466,081	4.5
Total assets acquired	$	58,228,155
Liabilities assumed:
Accounts payable	$	223,581
Other liabilities		452,541
Total liabilities assumed		676,122
Estimated fair value of net assets acquired	$	57,552,033

Engeni SA Acquisition

On ~~August 3, 2018 (the “Engeni~~the Engeni Closing ~~Date”),~~Date, the Company and its wholly owned subsidiary, Engeni Merger Sub, ~~LLC (“~~entered into the Engeni Merger ~~Sub”), entered into an~~ Agreement ~~and Plan of Merger (the “Engeni Merger Agreement”)~~ with Engeni ~~LLC (“~~US, Engeni ~~US”), Engeni S.A (“Engeni SA”), Scott Zienkewicz, Nicolas Heller and Alberto Pardo Saleme (the~~SA, the members of Engeni ~~US),~~US, and Scott Zienkewicz as the representative of the Engeni US members. Pursuant to the Engeni Merger Agreement, Engeni Merger Sub merged with and into Engeni US, with Engeni US surviving the merger as a wholly-owned subsidiary of the ~~Company (the “Engeni Merger”).~~Company. On the Engeni Closing Date, in connection with closing the Engeni Merger Agreement, the Company issued 366,700 shares of Company common stock to Engeni US members. Furthermore, the Company may also issue Engeni US members 366,700 and 366,600 shares of Parent common stock upon the achievement of specific objectives. If applicable, the Company will pay Engeni US members the aggregate amount of $100,000, on a pro rata basis, if Engeni SA reaches financial breakeven on or before December 31, 2018, as determined by the Company’s Chief Financial Officer and Scott Zienkewicz.

The Engeni Merger is being accounted for as a business combination in accordance with ASC 805. The Company has determined fair values of the assets acquired and liabilities assumed in the Engeni Merger. These values are subject to change as we perform additional reviews of our assumptions utilized.

During the first quarter of 2019, it was determined Engeni SA did not reach financial breakeven and therefore the contingent consideration of $100,000 was deemed by the Company not to be payable and was reduced to zero. In accordance with ASC 805-30-35-1, the Company recognized the change in the fair value of contingent consideration subsequent to the acquisition date in general and administrative expenses. The Company’s allocation of the purchase price was calculated as follows:

	As Adjusted
Base Price - Common Stock	$	388,702
Contingent Consideration - Common Stock		777,298
Contingent Consideration - Cash		-
Total Purchase Price	$	1,166,000

			Weighted Average Useful Life
Description	Fair Value		(in years)
Assets acquired:
Cash	$	5,609
Accounts receivable and other assets		30,479
Property, plant and equipment, net		57,830
Software		449,568	3.3
Goodwill		778,552
Total assets acquired	$	1,322,038
Liabilities assumed:
Accounts payable	$	56,038
Total liabilities assumed		56,038
Estimated fair value of net assets acquired	$	1,266,000

The Company determined the fair value of the contingent consideration to be $777,298 at August 3, 2018 and recorded it as a liability in its unaudited condensed consolidated balance sheets. On April 2, 2019, the Company satisfied their contingent consideration liability and issued 733,300 shares of the Company’s common stock to Engeni US members.

Tan’s International Security

On the Tan Security Closing Date, the Company entered into the Tan Security Acquisition Agreement. Pursuant to the Tan Security Acquisition Agreement, Helix purchased all membership interests and capital stock of Tan Security and collectively holds 100% of the interests of Tan Security. The purchase price of $100,000 in cash plus 250,000 shares of the Company’s restricted common stock will be paid to Rocky Tan as follows:

	●	250,000 shares of Helix Stock at closing.

	●	$25,000 at closing

	●	$25,000 on the 4-month anniversary of the Tan Security Closing Date

	●	$25,000 on the 8-month anniversary of the Tan Security Closing Date

	●	$25,000 on the 12-month anniversary of the Tan Security Closing Date

The Tan Security Acquisition is being accounted for as a business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed in the ~~Merger.~~Tan Security Acquisition. These values are subject to change as we perform additional reviews of our assumptions utilized.

The Company has made a provisional allocation of the purchase price of the ~~Merger~~Tan Security transaction to the assets acquired and the liabilities assumed as of the purchase date. The following table summarizes the provisional purchase price allocations relating to the ~~Merger transaction:~~Tan Security Acquisition:

Base Price - Common Stock $ 388,702
Contingent Consideration - Common Stock 777,298
Contingent Consideration - Cash 100,000
Total Purchase Price $ 1,266,000

Base Price – Cash at closing	$	25,000
Base Price – Deferred cash payment (including $25,000 to be made on the 4,8 and 12-month anniversaries of closing)		75,000
Base Price – Common Stock		710,000
Total Purchase Price	$	810,000

Weighted Average Useful Life
Description Fair Value (in years)
Assets acquired:
Cash $ 5,609
Accounts receivable and other assets 30,479
Property, plant and equipment, net 57,830
Software 449,568 3.3
Goodwill 778,552
Total assets acquired $ 1,322,038
Liabilities assumed:
Accounts payable $ 56,038
Total liabilities assumed 56,038
Estimated fair value of net assets acquired $ 1,266,000

Total acquisition costs for the Engeni merger incurred during the three and nine months ended September 30, 2018 was $38,409, and is included in selling, general and administrative expense in the Company’s Statements of Operations.

7.	~~Asset Acquisition~~

Description	Fair Value
Assets acquired:
Cash	$	2,940
Accounts receivable		7,635
Goodwill		821,807
Total assets acquired	$	832,382
Liabilities assumed:
Accounts payable	$	12,526
Other liabilities		9,856
Total liabilities assumed		22,382
Estimated fair value of net assets acquired	$	810,000

The Company has not completed the assessment necessary to finalize the acquisition fair values of the assets acquired and liabilities assumed and related allocation of ~~Revolutionary Software, LLC occurred via two transactions.~~

	1.	On March 14, 2016, the Company purchased one-third of the equity interest in Revolutionary for total consideration of $350,000 in cash and 75,000 shares of common stock of the Company. $50,000 was paid in cash at closing, with the balance ($300,000) being paid in twenty-four monthly installments of $10,417, with a final payment of $50,000 to be paid on the twenty-fifth month.

	2.	On April 11, 2016, the Company entered into an asset purchase agreement with Revolutionary, in which the Company purchased all of the intangible rights and property of Revolutionary for total consideration of $300,000 payable in two equal installments pursuant to a promissory note and 2,320,000 shares of restricted common stock of the Company. As of September 30, 2018, the Company owed Revolutionary $0.

~~The total~~ purchase price for Tan Security. Accordingly, the ~~Revolutionary assets acquired was $1,596,750. The acquisition cost has been allocated over~~type and value of the intangible assets ~~acquired in accordance with the guidance~~amounts set forth ~~in ASC 805,~~~~Business Combinations~~~~, please see Note 9. Intangible Assets and Goodwill, Net. As of September 30, 2018, and December 31, 2017,~~above are preliminary. Once the ~~Company has a liability pursuant~~valuation process is finalized for Tan Security, there could be changes to the ~~Revolutionary asset acquisition~~reported values of $0the assets acquired and ~~$58,370, respectively.~~

liabilities assumed, including goodwill and those changes could differ materially from what is presented above.

8.6.	Property and Equipment, Net

At ~~September~~June 30, ~~2018~~2019 and December 31, ~~2017,~~2018, property and equipment consisted of the following:

	September 30, 2018			December 31, 2017			June 30, 2019			December 31, 2018
Furniture and equipment	$	119,391		$	16,332		$	139,782		$	264,659
Software equipment		15,094			1,382			352,505			-
Vehicles		205,157			175,647			201,066			202,700
Total		339,642			193,361			693,353			467,359
Less: Accumulated depreciation		(59,118	)		(82,727	)		(147,535	)		(117,841	)
Property and equipment, net	$	280,524		$	110,634		$	545,818		$	349,518

Depreciation expense for the three months ended ~~September~~June 30, 2019 and 2018 was $29,509 and ~~2017 was $27,528 and $19,553,~~$32,893, respectively, and ~~$63,421~~$47,222 and ~~$42,589~~$35,893 for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, respectively.

9.7.	Intangible Assets, Net and Goodwill

The following table summarizes the Company’s intangible assets as of ~~September~~June 30, ~~2018~~2019 and December 31, ~~2017:~~2018:

				September 30, 2018										June 30, 2019
	Estimated Useful Life (Years)	Gross Carrying Amount		Assets Acquired Pursuant to Business Combination (2) (3)		Accumulated Amortization			Net Book Value		Estimated Useful Life (Years)	Gross Carrying Amount		Assets Acquired		Accumulated Amortization			Net Book Value
Database	5	$	93,427	$	-	$	(46,151	)	$	47,276	5	$	93,427	$	-	$	(60,119	)	$	33,308
Trade names and trademarks	5 - 10		125,000		466,081		(62,323	)		528,758	5 - 10		591,081		-		(149,063	)		442,018
Web addresses	5		130,000		-		(63,075	)		66,925	5		130,000		-		(82,511	)		47,489
Customer list	5		3,154,578		8,304,449		(1,388,176	)		10,070,851	5		11,459,027		-		(3,101,382	)		8,357,645
Software	4.5		-		9,771,195		(707,489	)		9,063,706	4.5		9,771,195		-		(2,356,189	)		7,415,006
Domain Name											5		-		17,383		(143	)		17,240
		$	3,503,005	$	18,541,725	$	(2,267,214	)	$	19,777,516		$	22,044,730	$	17,383	$	(5,749,407	)	$	16,312,706

				December 31, 2017										December 31, 2018
	Estimated Useful Life (Years)	Gross Carrying Amount at December 31, 2016		Assets Acquired Pursuant to Business Combination (1)		Accumulated Amortization			Net Book Value		Estimated Useful Life (Years)	Gross Carrying Amount at December 31, 2017		Assets Acquired Pursuant to Business Combination (1) (2)		Accumulated Amortization			Net Book Value
Database	5	$	93,427	$	-	$	(32,183	)	$	61,244	5	$	93,427	$	-	$	(50,858	)	$	42,569
Trade names and trademarks	10		100,000		25,000		(18,675	)		106,325	5 - 10		125,000		466,081		(91,554	)		499,527
Web addresses	5		125,000		5,000		(43,639	)		86,361	5		130,000		-		(69,625	)		60,375
Customer list	5		-		3,154,578		(366,249	)		2,788,329	5		3,154,578		8,304,449		(1,965,520	)		9,493,507
Software											4.5		-		9,771,195		(1,263,095	)		8,508,100
		$	318,427	$	3,184,578	$	(460,746	)	$	3,042,259		$	3,503,005	$	18,541,725	$	(3,440,652	)	$	18,604,078

(1)	~~On June 2, 2017, the Company acquired various assets of Security Grade Protective Services, Ltd. (See Note 6)~~
~~(2)~~	On June 1, 2018, the Company acquired various assets of BioTrackTHC (See Note 6)5)
~~(3)~~(2)	On August 3, 2018, the Company acquired various assets of Engeni (See Note 6)5)

The Company uses the straight-line method to determine the amortization expense for its definite lived intangible assets. Amortization expense related to the purchased intangible assets was ~~$1,160,889~~$1,160,827 and ~~$173,344~~$476,003 for the three months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, respectively, and ~~$1,806,468~~$2,308,755 and ~~$248,718~~$645,579 for the ~~nine~~six months ended ~~September~~June 30, 2019 and 2018, ~~and 2017,~~ respectively.

The following table summarizes the Company’s Goodwill as of ~~September~~June 30, 2019 and December 31, 2018:

Total Goodwill
Balance at January 1, 2018 $ 664,329
Impairment of goodwill (664,329 )
Goodwill attributable to Biotrack acquisition 39,135,007
Goodwill attributable to Engeni acquisition 778,552
Balance at September 30, 2018 $ 39,913,559

	Total Goodwill
Balance at December 31, 2017	$	664,329
Impairment of goodwill		(664,329	)
Goodwill attributable to BiotrackTHC acquisition		39,135,007
Goodwill attributable to Engeni acquisition		778,552
Balance at December 31, 2018	$	39,913,559
Goodwill attributable to Tan Security acquisition		821,807
Balance at June 30, 2019	$	40,735,366

During the ~~first quarter of~~period ended March 31, 2018, the Company came to a settlement agreement with ~~numerous~~multiple Security Grade employees resulting from a misrepresentation of revenue and customer list information provided as part of the acquisition. Therefore, the Company considers the settlement to be an indicator for goodwill impairment testing. Accordingly, at March ~~30,~~31, 2018, goodwill was tested for potential impairment. As a result of the goodwill impairment test performed, it was determined that the carrying value for each reporting unit was higher than its fair value and therefore goodwill was fully impaired, which resulted in a write-off of $664,329 for the ~~nine~~three months ended ~~September 30,~~March 31, 2018. As part of the BioTrack acquisition, Goodwill in the amount of $39,135,007 was recognized on the Company’s Condensed Consolidated Balance Sheet. As part of the Engeni US acquisition, Goodwill in the amount of $778,552 was recognized of the Company’s Condensed Consolidated Balance Sheet.

~~10.~~

~~Accounts Payable and Accrued Expenses~~

~~As of September 30, 2018 and December 31, 2017, accounts payable and accrued expenses consisted of the following:~~

September 30, 2018 December 31, 2017
Accounts payable $ 1,022,211 $ 334,751
Accrued expenses 284,183 220,682
Accrued interest 12,867 43,204
Total $ 1,319,261 $ 598,637

~~11.~~8.

Costs, Estimated Earnings and Billings

Costs, estimated earnings and billings on uncompleted contracts are summarized as follows as of ~~September~~June 30, ~~2018~~2019 and December 31, ~~2017:~~2018:

	September 30, 2018			December 31, 2017			June 30, 2019			December 31, 2018
Costs incurred on uncompleted contracts	$	118,741		$	64,705		$	140,289		$	89,700
Estimated earnings		50,261			27,731			49,366			50,512
Cost and estimated earnings earned on uncompleted contracts		169,002			92,436			189,655			140,212
Billings to date		147,996			71,778			304,500			252,535
Costs and estimated earnings in excess of billings on uncompleted contracts		21,006			20,658
Billings in excess of costs on uncompleted contracts								(114,845	)		(112,323	)

Costs in excess of billings	$	24,792		$	40,848		$	12,017		$	42,869
Billings in excess of cost		(3,786	)		(20,190	)		(126,862	)		(155,192	)
	$	21,006		$	20,658		$	(114,845	)	$	(112,323	)

9.	Accounts Payable and Accrued Liabilities

As of June 30, 2019 and December 31, 2018, accounts payable and accrued liabilities consisted of the following:

	June 30, 2019		December 31, 2018
Accounts payable	$	857,610	$	842,389
Accrued compensation and related expenses		56,332		33,869
Accrued expenses		1,138,368		826,455
Lease obligation - current		410,826		-
Total	$	2,463,136	$	1,702,713

~~12.~~10.

Convertible Note Payable

September 30, 2018 December 31, 2017
Note Five, 5% convertible promissory note, fixed secured, maturing May 16, 2018 $ 132,625 $ 812,393
132,625 812,393
Less: Current portion (132,625 ) (812,393 )
Long-term portion $ - $ -

On September 30, 2016, the Company entered into an Unsecured Convertible Promissory Note (“Note Four”) with a fourth investor (the “Fourth Investor”) in which the Fourth Investor provided the Company $500,000 in cash. As of December 31, 2016, the Class B Preferred Shares were not established as a result of Holder Default, in which, the Fourth Investor did not act in good faith towards the prompt negotiation, execution and delivery of the Class B Preferred Shares.

On March 31, 2017, the First Amendment to Note Four (the “Amended Note”) was entered by the Company and the Holder. In the absence of a Company Event of Default or Holder Event of Default, Amended Note is payable by issuance upon conversion into Class B Preferred Shares of the Company, which was to occur no later than June 1, 2017. The Amended Note had the following conversion features:

	●	~~Automatic Conversion.~~The principal balance of the Amended shall automatically convert into shares of Class B Preferred Shares upon execution by the Company and the Fourth Investor of definitive documentation relating to the $500,000, aggregate principal amount, and investment by the Fourth Investor in Class B Preferred Shares of the Company.

	●	~~Company Default.~~In the event of a Company Event of Default, the Fourth Investor the shall have the right to elect to (i) at any time prior to June 30, 2017, convert the aggregate outstanding principal amount of Note Four into Class B Preferred Shares equal to 6.3% of the Company’s equity capital calculated on a fully-diluted basis, or (ii) at any time commencing on July 1, 2017 and ending on September 31, 2017, have Note Four redeemed for cash at a redemption price, in aggregate, equal to 150% of the aggregate principal outstanding balance of Note Four or (iii) to convert Note Four into common shares of the Company equal to 6.3% of the Company’s equity capital calculated on a fully-diluted basis. In the event the Holder does not elect any remedy in the event of a Company Event of Default, on September 31, 2017 the Amended Note shall be converted in whole into common shares of the Company equal to 6.3% of the Company’s equity capital calculated on a fully-diluted basis.

	●	~~Holder Default.~~In the event of a Holder Event of Default, the Company shall have the right to either (i) redeem the Amended Note at par value at any time prior to June 1, 2017 or (ii) convert the outstanding principal balance into common shares of the Company at market value.

	●	The Valuation and Consideration provision in Section 2 of the Term Sheet is affirmed and ratified; provided, however, that the parties agree that the $12,000,000 valuation therein is subject to dilution of $600,000 from additional investments in the Company by third parties following the Holder’s $500,000 investment that is memorialized in the Note. For the avoidance of doubt, the Holder will receive the same number of shares as it would have for its investment if it had converted at a $12,000,000 valuation on October 20, 2016 given the 26,587,497 shares outstanding at that time. For the avoidance of doubt, the Note will convert into 1,162,500 shares.

Due to the terms of the Amendment, the Company evaluated Note Four under ASC 470-50 to determine if modification or extinguishment treatment was necessary. After performing the analysis under ASC 470-50, it was determined extinguishment treatment was appropriate and the Company should extinguish Note Four and recognize the Amended Note as new debt. The Company recognized a loss on extinguishment of $4,611,395 on Note Four.

The Company evaluated the Amended Note and the embedded conversion feature under ASC 815 and determined the conversion feature did not meet the definition of a derivative and therefore should not be bifurcated. The Company then evaluated the Amended Note in accordance with ASC 480 and determined that Note Four will be accounted for as a liability measured at fair value. As of March 31, 2017, the fair value of the liability was $500,000.

	June 30, 2019			December 31, 2018
Note Five, 5% interest, convertible promissory note, fixed secured, maturing November 16, 2019	$	-		$	187,177
Note Ten, 25% interest, convertible promissory note, fixed secured, maturing March 1, 2020, net of debt discount for warrants		423,700			-
		423,700			187,177
Less: Current portion		(423,700	)		(187,177	)
Long-term portion	$	-		$	-

On February 13, 2017, the Company entered into a $183,333 10% Fixed Secured Convertible Promissory Note (“Note Five”) with ~~a third~~an investor (the ~~“Third~~“First Investor”). The ~~Third~~First Investor provided the Company with $166,666 in cash, which was received by the Company during the period ended March 31, 2017. The additional $16,666 was retained by the ~~Third~~First Investor for due diligence and legal bills for the transaction. The Company promised to pay the principal amount, together with guaranteed interest at the annual rate of 10%, with principal and accrued interest on Note Five due and payable on September 12, 2017 (unless converted under terms and provisions as set forth within Note Five). The principal balance of Note Five was convertible at the election of the Third Investor, in whole or in part, at any time or from time to time, into the Company’s common stock at $1.50 per share. In conjunction with Note Five, the Company issued a warrant to the third investor to purchase 25,000 shares of the Company’s common stock at $1.00 per share. Note Five became effective on February 14, 2017 upon the execution by the Company and the Holder of numerous exhibit documents. In addition, the Company reserved 2,500,000 shares of the Company’s common stock for the Third Investor.

The Company evaluated the embedded conversion feature within the above convertible note under ASC 815 and determined the conversion feature did not meet the definition of a derivative and therefore should not be bifurcated. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception. The Company accounted for the intrinsic value of a Beneficial Conversion Feature inherent to the convertible note payable and a total debt discount of $183,333 was recorded.

The Company recorded a debt discount relating to the warrants issued in the amount of $22,000 based on the relative fair values of Note Five without the warrants and the warrants themselves at the effective date of Note Five. The additional $16,666 retained by the ~~Third~~First Investor for due diligence and legal bills for the transaction will be recorded as a debt discount. The calculated value of the beneficial conversion feature and the combined value of the debt discount resulted in a value greater than the value of the debt and as such, the total discount was limited to the value of the debt balance of $183,333. Therefore, the debt discount related to the ~~Beneficial Conversion Feature~~beneficial conversion feature was in the amount of $144,666. The excess value of the Beneficial Conversion Feature discount was recognized as a loss in earnings and recorded as an interest expense in the amount of $390,666 and will be amortized through Maturity of Note Five.

The debt discounts will be amortized to interest expense over the life of the note. Amounts amortized to interest expense were approximately $39,286 for the three months ended March 31, 2017. The unamortized discount balance at March 31, 2017 was approximately $144,047.

On February 13, 2017, the Company entered into a $25,000 10% Fixed Secured Convertible Promissory Note (“Note Six”) with a third investor (the “Third Investor”). The Third Investor provided the Company with $25,000 in cash, which was received by the Company during the period ended March 31, 2017. The Company promised to pay the principal amount, together with guaranteed interest at the annual rate of 10%, with principal and accrued interest on Note Six due and payable on September 13, 2017. The principal balance of Note Six was convertible at the election of the Third Investor, in whole or in part, at any time or from time to time, into the Company’s common stock at $6.10 per share. Note Six become effective on February 14, 2017 upon the execution by the Company and the Holder of numerous exhibit documents.

The Company evaluated Note Six in accordance with ASC 815 to determine if the conversion feature should be bifurcated and accounted for at fair value and remeasured at fair value in income. The Company determined that the conversion feature did not meet the requirements for bifurcation pursuant to ASC 815. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception and determined that Note Six did not have a beneficial conversion feature. As a result, the Company recorded the conventional convertible note as a debt instrument in its entirety. The interest expense associated with Note Six was $536 for the period ended March 31, 2017.

On April 26, 2017, the Company entered into a $100,000 10% Secured Convertible Promissory Note (“Note Seven”) with a fourth investor (the “Fourth Investor”). The Fourth Investor provided the Company with $72,000 in cash proceeds, which was received by the Company during the three months ended June 30, 2017. Note Seven is due on October 26, 2017 and the Company must pay guaranteed interest on the principal balance at an amount equivalent to 10% of the note amount. The principal balance of Note Seven is convertible at the election of the Fourth Investor, in whole or in part, at any time or from time to time, into the Company’s common stock at the lower of $1.00 or a 50% discount to the lowest closing bid price of the Company’s common stock for the 30 Trading Days prior to conversion. In conjunction with Note Seven, the Company issued a warrant to the fourth investor to purchase 150,000 shares of the Company’s common stock at $1.00 per share.

On November 16, 2017, the Company amended ~~Notes~~Note Five ~~Six, and Seven (“the Amended Notes”~~(the “First Amendment”) with the ~~Fourth~~First Investor. ~~All three notes shall have~~The First Amendment has a maturity ~~dates~~date that ~~are~~is six months from November 16, 2017, ~~shall convert~~converts at a 40% discount to the lowest one-day Volume Average Weighted Price (“VWAP”) during the 30 trading days preceding such conversion, ~~shall incur~~incurs interest at an annual rate of 5%, and ~~shall be~~is prepayable at any time at 110% of the unpaid principal and accrued interest balances. The amendment of Note Six and Seven included terms, permitting the Company the option to tender payment in full on or before November 21, 2017, at a 15% discount of the amended principal amounts.balance. At November 16, 2017, the principal ~~amounts~~amount of Note Five Six and Seven were $281,900, $38,441 and $131,107, respectively. On November 21, 2017, the Company paid the remaining principal balance, at the 15% discount on Notes Six and Seven in the amount of $144,259.was $281,900.

On May 16, 2018, the Company amended Note Five (“Second Amendment”) with the ~~Fourth~~First Investor. The Second Amendment states that Note Five shall have a maturity of November 16, 2018 and shall be ~~prepayable~~pre-payable at any time at 120% of the unpaid principal and accrued interest balance. The principal amount as of the date of the Second Amendment was $112,305.

In November 2018, the Company amended Note Five (“Third Amendment”) with a second investor. The Third Amendment states that Note Five shall have a maturity of November 16, 2019. The principal amount as of the date of the Third Amendment was $115,136. During March 2019, the remaining principal of $112,305 was converted into 155,421 shares of common stock. The interest expense associated with Note Five was $0 and $5,839 for the three months ended June 30, 2019 and 2018, respectively, and $0 and $7,878 for the six months ended June 30, 2019 and 2018, respectively.

On March 1, 2019, the Company entered into a $450,000 Secured Convertible Promissory Note (“Note Ten”) with a third investor. The third investor provided the Company with $450,000 in cash proceeds, which was received by the Company during the period ended June 30, 2019. Note Ten will mature on March 1, 2020 and bear interest at a rate of 25% per annum, payable by the Company half in cash and half in kind on a quarterly basis. The principal balance of Note Ten is convertible at the election of the third investor, in whole or in part, at any time or from time to time, into the Company’s common stock at the lower of $0.90 per share or a 30% discount to the Company’s 30-day weighted average listed price per share immediately before the date of conversion. In conjunction with Note Ten, the Company issued a warrant to the third investor to purchase 160,715 shares of the Company’s common stock at $1.40 per share.

The Company evaluated Note ~~Five~~Ten in accordance with ASC 480, Distinguishing Liabilities from Equity and determined ~~the~~ Note ~~Five~~Ten will be accounted for as a liability initially measured at fair value and subsequently at fair value with changes in fair value recognized in earnings. As of ~~September~~June 30, ~~2018, and December 31, 2017,~~2019, the fair value of Note ~~Five~~Ten was ~~$132,625 and $812,393, respectively. Therefore,~~$661,581. Accordingly, the Company recorded a ~~(loss) gain to the~~ change in fair value of ~~$(17,880)~~($845,622) and ~~$679,766~~$211,581 related to Note ~~Five~~Ten for the three and ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, respectively.

In addition, the company recorded a debt discount relating to the warrants issued in the amount of $355,847 based on the residual fair value of the warrants themselves at inception of Note Ten. Debt discounts amortized to interest expense were $88,718 and $117,966 for the three and six months ended June 30, 2019, respectively. The unamortized discount balance at June 30, 2019 was $237,881. On May 31, 2019, the Company issued 15,625 restricted shares of common stock as paid-in-kind (“PIK”) interest payments in the amount of $14,062. Accrued interest expense associated with Note Ten was $9,247 as of June 30, 2019, which includes PIK interest payable.

~~13.~~11.

Related Party Transactions

Advances from Related Parties

The Company ~~has~~had a loan outstanding from a former Company executive. The ~~advance does not accrue interest and has no definite repayment terms. The~~ loan balance was ~~$55,250~~$0 and ~~$124,750~~$45,250 as of ~~September~~June 30, ~~2018~~2019 and December 31, ~~2017,~~2018, respectively.

Convertible Note Payable

On March 11, 2016, the Company entered into an Unsecured Convertible Promissory Note (“Note Eight”) with Paul Hodges, a Director of the Company (the “Related Party Holder”). The Related Party Holder provided the Company with $150,000 in cash, and the Company promised to pay the principal amount, together with interest at an annual rate of 7%, with principal and accrued interest on Note ~~Five~~Eight due and payable on December 31, 2017 (unless converted under terms and provisions as set forth below). The principal balance of Note Eight was convertible at the election of the Related Party Holder, in whole or in part, at any time or from time to time, into the Company’s common stock at a forty percent (40%) discount to the average market closing price for the previous five (5) trading days, preceding the date of conversion election. The Company evaluated Note Eight in accordance with ASC 480,Distinguishing Liabilities from Equity and determined that Note Eight will be accounted for as a liability initially measured at fair value and subsequently at fair value with changes in fair value recognized in earnings.

On February 20, 2018, the Company entered into an agreement to amend Note Eight ~~(this~~(the “Amendment”) with the Related Party ~~Holder March 2016 (the “Note”).~~Holder. The Company and ~~Holders desire~~Holder desired to extend the maturity date of ~~the~~ Note Eight to August 20, ~~2018.~~

~~The~~2018 (the “Maturity Date”). Note ~~is hereby~~Eight was amended as follows. The Company promises to pay (i) all accrued interest on the unpaid principal amount through December 31, 2017 and (ii) $25,000 in principal within 5 business days of the date of ~~this~~the Amendment. The Company agrees to issue 15,000 shares of restricted Company common stock as an inducement for ~~this amendment~~the Amendment within 10 business days of the date of ~~this~~the Amendment. The principal amount of ~~the note~~Note Eight will be reduced to $125,000. Unless extended by the Company, converted or prepaid earlier, all unpaid principal and unpaid accrued interest on ~~this~~ Note Eight shall be due and payable on ~~August 20, 2018 (the “Maturity Date”).~~the Maturity Date. All provisions related to conversion of ~~the~~ Note Eight into equity securities of the Company were terminated as part of ~~this~~the Amendment.

As of February 20, 2018, the fair value of the liability was $239,343, however due to termination of the conversion of the note into equity securities, Note Eight will be valued in its principal amount of $125,000 and accordingly the Company recorded a credit regarding the change in fair value of $0 ~~and charge of $34,725~~ for the three months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, respectively, and ~~$118,506~~$0 and ~~$8,971~~$118,506 for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, respectively. The interest expense associated with Note ~~Five~~Eight was ~~$2,479 and $2,675~~$0 for the three months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, respectively, and ~~$10,217~~$0 and ~~$7,853~~$2,402 for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, respectively. Note Eight was paid in full on the Maturity Date.

On March 1, 2019, the Company entered into a $1,500,000 Secured Convertible Promissory Note (“Note Nine”) with a related party entity (the Second Related Party Holder”). A Managing Member of the Second Related Party Holder is also a Director of the Company. The Second Related Party Holder provided the Company with $1,475,000 in cash proceeds, which was received by the Company during the period ended June 30, 2019. The additional $25,000 was retained by the fourth investor for legal bills for the transaction. Note Nine will mature on March 1, 2020 and bear interest at a rate of 25% per annum, payable by the Company half in cash and half in kind on a quarterly basis. The principal balance of Note Nine is convertible at the election of the fourth investor, in whole or in part, at any time or from time to time, into the Company’s common stock at the lower of $0.90 per share or a 30% discount to the Company’s 30-day weighted average listed price per share immediately before the date of conversion. In conjunction with Note Nine, the Company issued a warrant to the fourth investor to purchase 535,715 shares of the Company’s common stock at $1.40 per share.

The Company evaluated Note Nine in accordance with ASC 480, Distinguishing Liabilities from Equity and determined Note Nine will be accounted for as a liability initially measured at fair value and subsequently at fair value with changes in fair value recognized in earnings. As of June 30, 2019, the fair value of Note Nine was $2,205,270. Accordingly, the Company recorded a change in fair value of ($2,818,739) and $705,270 related to Note Nine for the three and six months ended June 30, 2019, respectively.

In addition, the company recorded a debt discount relating to the warrants issued in the amount of $1,186,153 based on the residual fair value of the warrants at inception of Note Nine. The additional $25,000 retained by the fourth investor for legal bills for the transaction will be recorded as a debt discount. Debt discounts amortized to interest expense were $301,959 and $401,506 for the three and six months ended June 30, 2019, respectively. The unamortized discount balance at June 30, 2019 was $809,647. On May 31, 2019, the Company issued 52,083 restricted shares of common stock as PIK interest payments in the amount of $46,875. Accrued interest expense associated with Note Nine was $30,822 as of June 30, 2019, which includes PIK interest payable. As of June 30, 2019, the balance of Note Nine, net of debt discount for warrants and legal bills was $1,395,623.

Warrants

In March 2016, the Company issued 960,000 shares of restricted common stock to the Related Party Holder per a subscription agreement for total proceeds of $150,000. In conjunction with the subscription agreement, the Company issued a warrant to the Related Party Holder to purchase 1,920,000 restricted shares of the Company’s common stock at $0.16 per share. The Warrant Exercise Date is the later of the following to occur (i) March 9, 2017, (ii) ten (10) days after the Company’s notice to the holder of the warrant that the Company shall have an effective S-1 registration with the SEC; or (iii) ten (10) days after Company’s notice to the holder of the warrants that the Company has entered into an agreement for the sale of substantially all the assets or Common Stock of the Company. As of ~~September~~June 30, ~~2018,~~2019, the warrants granted are not exercisable.

On March 1, 2019, in connection with the issuance of Note Nine, the Company issued warrants, of which the value was derived and based off the fair value of Note Nine, to the investor to purchase 535,715 shares of the Company’s common stock at $1.40 per share. Exercise of the purchase rights represented by the warrant may be made, in whole or in part, at any time or times on or after March 1, 2019 and on or before March 1, 2024, by delivery to the Company of the Notice of Exercise.

The Company determined that the warrants associated with Note Nine are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity. The Company has no plans to consummate a fundamental transaction and does not believe a fundamental transaction is likely to occur during the remaining term of the outstanding warrants. In accordance with the accounting guidance, the outstanding warrants are recognized as a warrant liability on the balance sheet and are measured at their inception date fair value and subsequently re-measured at each reporting period with changes being recorded as a component of other income in the statement of operations. At inception, March 1, 2019, the fair value of the warrant liability was $1,186,153 while as of June 30, 2019, the fair value of the warrant liability was $471,346. Accordingly, the Company recorded a change in fair value of $(857,730) and $(714,807) during the three and six months ended June 30, 2019, respectively, which is reflected in the unaudited condensed consolidated statements of operations.

Promissory Note

On ~~August 29, 2018, the Company entered into an unsecured promissory note with an affiliate of an investor of the Company. Refer to Note 14 for additional details regarding the unsecured promissory note.~~

~~14.~~

~~Promissory Notes~~

~~On February 13, 2017,~~January 3, 2019, the Company entered into an unsecured promissory note in the amount of ~~$180,000.~~$280,000. The unsecured promissory note has a fixed interest rate of 8% and was due and payable on June 30, 2017. In conjunction with the Series B Preferred Stock Purchase Agreement, as discussed in Note 16, the Company satisfied its liability in exchange for Series B Preferred Stock. The interest expense associated with the unsecured promissory note was $0 for the three months ended September 30, 2018 and 2017, respectively and $0 and $2,570 for the nine months ended September 30, 2018 and 2017, respectively.

On January 30, 2017, the Company entered into an unsecured promissory note in the amount of $75,000. The unsecured promissory note had a fixed interest rate of 8% and was due and payable on June 30, 2017. In conjunction with the Series B Preferred Stock Purchase Agreement, as discussed in Note 16, the Company satisfied its liability in exchange for Series B Preferred Stock. The interest expense associated with the unsecured promissory note was $0 for the three months ended September 30, 2018 and 2017, respectively and $0 and $2,570 for the nine months ended September 30, 2018 and 2017, respectively.

~~On August 29, 2018, the Company entered into an unsecured promissory note in the amount of $250,000. The unsecured promissory note has a fixed interest rate of 7%~~10% and is due and payable on ~~July~~March 31, 2019. ~~As of September 30, 2018 and December 31, 2017, the Company had $250,000 and $0 outstanding on the unsecured promissory note. The interest expense associated with~~On March 2, 2019, the unsecured promissory note was ~~$1,534 and $0 for the three months ended September 30, 2018 and 2017, respectively, and $1,534 and $0 for the nine months ended September 30, 2018 and 2017, respectively.~~paid off in full.

~~15.~~12.

Notes Payable

September 30, 2018 December 31, 2017
Vehicle financing loans payable, between 4.7% and 7.0% interest and maturing between June 2022 and July 2022 $ 75,090 $ 55,890
Loans Payable - Credit Union 5,653 8,582
Less: Current portion of loans payable (7,582 ) (11,179 )
Long-term portion of loans payable $ 73,161 $ 53,293

Notes payable consisted of the following:

	June 30, 2019			December 31, 2018
Vehicle financing loans payable, between 4.7% and 7.0% interest and maturing between June 2022 and July 2022	$	58,910		$	71,284
Loans Payable - Credit Union		6,127			5,075
Less: Current portion of loans payable		(24,805	)		(24,805	)
Long-term portion of loans payable	$	40,232		$	51,554

The interest expense associated with the notes payable was ~~$2,901~~$890 and ~~$230~~$720 for the three months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, respectively, and ~~$4,321~~$2,681 and ~~$600~~$1,420 for the ~~nine~~six months ended ~~September~~June 30, 2019 and 2018, ~~and 2017,~~ respectively.

~~16.~~13.

Shareholders’ Equity

Common Stock

Subscription Agreements

~~In February 2018, the Company issued 222,222~~The table below reflects shares of restricted common stock issued in relation to ~~an investor per a~~ subscription ~~agreement for total proceeds of $200,000.~~agreements during the period ended June 30, 2018:

~~In March 2018, the Company issued 500,000 shares of restricted common stock to an investor per a subscription agreement for total proceeds of $450,000.~~

Date of Sale	Number of Shares Sold		Total Proceeds
February 2018		222,222	$	200,000
March 2018		500,000		450,000
April 2018		500,000		450,000
May 2018		244,444		219,999
		1,466,666	$	1,319,999

~~In April 2018, the Company issued 500,000 shares of restricted common stock to an investor per a subscription agreement for total proceeds of $450,000.~~

~~In May 2018, the Company issued 244,444 shares of restricted common stock to an investor per a subscription agreement for total proceeds of $220,000.~~

~~In July 2018, the Company issued 327,777 shares of restricted common stock at $0.90 per share to an investor per a subscription agreement for total proceeds of $294,999.~~

~~In August 2018, the Company issued 327,777 shares of restricted common stock at $0.90 per share to an investor per a subscription agreement for total proceeds of $294,999.~~

~~In August 2018, the Company issued 183,333 shares of restricted common stock at $0.90 per share to an investor per a subscription agreement for total proceeds of $164,999.~~

~~In September 2018, the Company issued 577,778 shares of restricted common stock at $0.90 per share to an investor per a subscription agreement for total proceeds of $520,000.~~

Other Common Stock Issuances

~~In May 2018, the Company issued 50,000 shares of restricted common stock to a consultant per a consulting agreement.~~

In June 2018, the Company issued 38,184,985 shares of common stock as part of the ~~BioTrack~~BioTrackTHC acquisition.

InOn June 7, 2018, two selling shareholders of Security Grade exercised their right to purchase 212,633 shares of the Company’s common stock.

In ~~July 2018, one~~January 2019, the Company issued 20,000 shares of restricted common stock to a consultant per a consulting agreement and recorded shared based compensation expense of $27,400.

In March and June 2019, the Company issued 1,255,222 and 166,667 shares of common stock as part of investment unit purchase agreements (see Note 15).

In March and June 2019, certain option holders exercised their rights under the BioTrackTHC Stock Plan and were issued 62,847 and 47,084 shares of common stock, respectively, for no cash proceeds.

In March and April 2019, certain option holders exercised their rights under the BioTrackTHC Stock Plan and were issued 6,082 and 57,461 shares of common stock for total proceeds of $4,805 and $21,808, respectively.

In April 2019, the Company issued 250,000 shares of common stock as part of the Tan Security acquisition.

In April 2019, a selling shareholder of Security Grade exercised their right to purchase ~~3,983~~15,101 shares of the Company’s common stock.

In ~~July 2018,~~April 2019, the Company issued ~~200,000~~733,300 shares of ~~restricted~~ common stock ~~to consultants as an inducement to enter into a leak-out agreement with~~in satisfaction of the ~~Company.~~Engeni contingent consideration (see Note 5).

In ~~August 2018,~~May 2019, the Company issued ~~100,000 shares of~~15,625 and 52,083 restricted ~~common stock as part of an agreement entered into with an investor relation consultant.~~

~~In August 2018, the Company issued 366,700~~ shares of common stock as ~~part~~PIK interest payments in the amount of ~~the Engeni US acquisition.~~$14,062 and $46,875, respectively (see Notes 10 and 11).

Conversion of Convertible Note to Common Stock

On February 15, 2018, March 12, 2018 and March 21, 2018, the holder of a 10% fixed secured convertible promissory note issued by the Company elected ~~their~~its option to partially convert $50,000, $50,000 and $75,000 in principal of the convertible note into 46,066, 63,963, and 95,945 shares of the Company’s common stock.

On March ~~12, 2018, the same holder partially converted an additional $50,000 in principal of the convertible note into 63,963 shares of the Company’s common stock.~~

On7, 2019 and March ~~21, 2018, the same holder partially converted an additional $75,000 in principal of the convertible note into 95,945 shares of the Company’s common stock.~~

~~Amended Convertible Note~~

On February 20, 2018, the Company entered into an agreement to amend a Convertible Promissory Note with the undersigned holder initially issued to such Holder and dated March 2016. The Company and Holders desire to extend the maturity date of the Note to August 20, 2018. The holder was issued 15,000 shares of the Company’s restricted common stock as part of the amendment.

The Note is hereby amended as follows. The Company promises to pay (i) all accrued interest on the unpaid principal amount through December 31, 2017 and (ii) $25,000 in principal within 5 business days of the date of this Amendment. The Company agrees to issue 15,000 shares of restricted Company common stock as an inducement for this amendment within 10 business days of the date of this Amendment. The principal amount of the note will be reduced to $125,000. Unless extended by the Company, converted or prepaid earlier, all unpaid principal and unpaid accrued interest on this Note shall be due and payable on August 20, 2018 (the “Maturity Date”). All provisions related to conversion of the Note into equity securities of the Company are hereby deleted.

~~On May 16, 2018, the Company entered into a second amendment agreement of a Convertible Promissory Note with~~28, 2019, the holder of a 10% fixed secured convertible promissory ~~note. The new Maturity Date is November 16, 2018. The new interest rate is 5%. The~~ note ~~is prepayable at 120%~~issued by the Company elected its option to fully convert $75,882 and $42,055 in principal of the ~~unpaid balance upon 10 business days’ notice to~~convertible note into 100,000 and 55,421 shares of the holder, which has the option to convert, in whole or in part, during the notice period. The conversion price shall be equal to a 40% discount to the lowest one-day Volume Average Weighted Price (“VWAP”) during the 30 trading days preceding such conversion.Company’s common stock.

2017 Omnibus Incentive Plan

~~On January 11, 2018, the Company~~The table below reflects shares issued ~~42,850 shares of the Company’s restricted common stock~~ under the 2017 Omnibus Incentive Plan ~~to select personnel of~~during the ~~Company. Additionally, on March 15, 2018, the Company issued an additional 100,000 shares of the Company’s common stock to select employees of the Company.~~period ended June 30, 2019:

Date of Issuance	Number of Shares Issued		Total Share Based Compensation
March 2019		250,000	$	320,000
		250,000	$	320,000

~~In May 2018, the Company~~

The table below reflects shares issued ~~83,900 shares of common stock to various employees pursuant to~~under the ~~Company’s~~ 2017 Omnibus ~~Stock~~ Incentive ~~Plan.~~Plan during the period ended June 30, 2018:

~~In July 2018, the Company issued 100,000 shares of common stock to various employees pursuant to the Company’s 2017 Omnibus Stock Incentive Plan.~~

Date of Issuance	Number of Shares Issued		Total Share Based Compensation
January 2018		42,850	$	173,014
March 2018		100,000		250,000
May 2018		133,900		223,774
		276,750	$	646,788

~~In August 2018, the Company issued 43,195 shares of common stock to various employees pursuant to the Company’s 2017 Omnibus Stock Incentive Plan.~~

Series A convertible preferred stock

In October 2015, the Company issued a total of 1,000,000 shares of its Class A Preferred Stock as part of a reorganization in which Helix Opportunities LLC contributed 100% of itself and its wholly-owned subsidiaries, Security Consultants Group, LLC and Boss Security Solutions, Inc. to the Company in exchange for 1,000,000 convertible preferred shares of the Company. The Class A Preferred Stock included super majority voting rights and were convertible into 60% of the Company’s common stock. During the third quarter of 2017, the Company modified the conversion rate on the Class A Preferred Stock to a 1:1 ratio. This modification reduced the amount of potentially dilutive Convertible Series A Stock by 15,746,127 shares to a total of 1,000,000 at September 30, 2017.

Series B convertible preferred stock

Series B Preferred Stock Purchase Agreement

On May 17, 2017, the Company sold to accredited investors an aggregate of 5,781,426 Series B Preferred Shares for gross proceeds of $1,875,000 and converted a $500,000 Unsecured Convertible Promissory Note into 1,536,658 Series B Preferred Shares. This tranche of Series B Preferred Shares are convertible into 7,318,084 shares of common stock based on the current conversion price, at a purchase price of $0.325 per share. Net proceeds were approximately $1,772,500 after legal and placement agent fees listed below and the satisfaction of the promissory notes discussed in Note ~~14.~~11.

In connection with the Series B Preferred Stock Purchase Agreement, the Company is obligated to issue warrants to a third-party for services to purchase 462,195 shares of common stock at $0.325 per share (see Note 18). These warrants have been accounted for as an obligation to issue because as of the balance sheet date the Company did not deliver the warrants though incurred the obligation; accordingly, they were recognized as a liability on the unaudited condensed consolidated balance sheet and cost of issuance of Series B preferred shares on the unaudited condensed consolidated statement of shareholders’ ~~equity (deficit).~~equity.

~~On July 28, 2017, as contemplated by~~The table below reflects the ~~Initial~~shares issued under the Series B Preferred Purchase Agreement the Parties entered into a second Series B Preferred Stock Purchase Agreement (the “Second Series B Purchase Agreement”) whereby the Company issued and sold to accredited investors 1,680,000 shares of the ~~Company’s Series B Preferred Stock in exchange for an aggregate cash payment equal to $840,000.~~

~~On August 29, 2017, as contemplated by the Initial~~initial tranche, Second Series B Purchase Agreement and the ~~Parties entered into a third Series B Preferred Stock Purchase Agreement (the “Third Series B Purchase Agreement”) whereby~~various issuances under the ~~Company issued and sold to accredited investors 369,756 shares of the Company’s Series B Preferred Stock in exchange for an aggregate cash payment equal to $120,000.~~

~~On September 15, 2017, as contemplated by the Initial~~Third Series B Purchase Agreement during the Parties entered into a fourth Series B Preferred Stock Purchase Agreement (the “Third Series B Purchase Agreement”) whereby the Company issued and sold to accredited investors 462,195 shares of the Company’s Series B Preferred Stock in exchange for an aggregate cash payment equal to $150,000.year-ended December 31, 2017:

Date of Sale	Number of Shares Sold		Total Proceeds
Initial
May 2017		7,318,084	$	1,875,000
Second
July 2017		1,680,000		840,000
Third
August 2017		369,756		120,000
September 2017		462,195		150,000
October 2017		462,195		150,000
October 2017		1,042,337		557,500
December 2017		2,449,634		795,000
Ending Balance		13,784,201	$	4,487,500

On October 11, 2017, as contemplated by the Initial Series B Purchase Agreement, the Parties entered into a fifth Series B Preferred Stock Purchase Agreement (the “Third Series B Purchase Agreement”) whereby the Company issued and sold to accredited investors 462,195 shares of the Company’s Series B Preferred Stock in exchange for an aggregate cash payment equal to $150,000.

On October 31, 2017, as contemplated by the Initial Series B Purchase Agreement, the Parties entered into a sixth Series B Preferred Stock Purchase Agreement (the “Third Series B Purchase Agreement”) whereby the Company issued and sold to accredited investors 1,042,337 shares of the Company’s Series B Preferred Stock in exchange for an aggregate cash payment equal to $557,500.

On December 19, 2017, as contemplated by the Initial Series B Purchase Agreement, the Parties entered into a seventh Series B Preferred Stock Purchase Agreement (the “Third Series B Purchase Agreement”) whereby the Company issued and sold to accredited investors 2,449,634 shares of the Company’s Series B Preferred Stock in exchange for an aggregate cash payment equal to $795,000.

~~Series B Preferred Stock~~

In accordance with the Certificate of Incorporation, there were 9,000,000 authorized Series B Preferred Stock at a par value of $ ~~0.001~~.0.001. In connection with the Series B Preferred Stock Purchase Agreement, on May 12, 2017, the Company filed a Certificate of Designation (the “Certificate of Designations”) with the Secretary of State of the State of Delaware to designate the preferences, rights and limitations of the Series B Preferred Shares. On August 23, 2017 the Certificate of Designations was amended and restated to increase the number of shares of Series B Preferred Stock authorized to be 17,000,000.

Conversion:

Each Series B Preferred Share is convertible at the option of the holder ~~at any time on or after May 12, 2018~~ into such number of shares of the Company’s common stock equal to the number of Series B Preferred Shares to be converted, multiplied by the Preferred Conversation Rate. The Preferred Conversion Rate shall be the quotient obtained by dividing the Preferred Stock Original Issue Price ($0.3253815) by the Preferred Stock Conversation Price in effect at the time of the conversion (the initial conversion price will be equal to the Preferred Stock Original Issue Price, subject to adjustment in the event of stock splits, stock dividends, and fundamental transactions). Based on the current conversion price, the Series B Preferred Shares are convertible into ~~13,306,599~~13,784,201 shares of common stock. A fundamental transaction means: (i) our merger or consolidation with or into another entity, (ii) any sale of all or substantially all of our assets in one transaction or a series of related transactions, (iii) any reclassification of our Common Stock or any compulsory share exchange by which Common Stock is effectively converted into or exchanged for other securities, cash or property; or (iv) sale of shares below the preferred stock conversion price. Each Series B Preferred Share will automatically convert into common stock upon the earlier of (i) notice by the Company to the holders that the Company has elected to convert all outstanding Series B Preferred Shares at any time on or after May 12, 2018; or (ii) immediately prior to the closing of a firmly underwritten initial public offering (involving the listing of the Company’s Common Stock on an Approved Stock Exchange) pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of the Common Stock for the account of the Company in which the net cash proceeds to the Company (before underwriting discounts, commissions and fees) are at least fifty million dollars ($50,000,000).

Beneficial Conversion Feature – Series B Preferred Stock (deemed dividend):

Each share of Series B Preferred Stock is convertible into shares of common stock, at any time at the option of the holder at any time on or after May 12, 2018. On May 17, 2017, the date of issuances of the Series B, the publicly traded common stock price was $3.98.

Based on the guidance in ASC 470-20-20, the Company determined that a beneficial conversion feature exists, as the effective conversion price for the Series B preferred shares at issuance was less than the fair value of the common stock into which the preferred shares are convertible. A beneficial conversion feature based on the intrinsic value at the date of issuances for the Series B preferred shares is scheduled below. For the three and ~~nine~~six months ended ~~September~~June 30, 2018, the beneficial conversion amount of $14,998,505 and $22,202,194, respectively was accreted back to the preferred stock as a deemed dividend and charged to additional paid in capital in the absence of earning as the beneficial conversion feature is amortized over time through the earliest conversion date, May 12, 2018. ~~As of June 30, 2018 the beneficial conversion feature was fully amortized.~~ Provided below is a schedule of the issuances of Series B preferred shares and the amount accredited to deemed dividend at ~~September~~June 30, 2018. As of June 30, 2019 and 2018, the beneficial conversion feature was fully amortized.

For the Six Months Ended June 30, 2018
Issuance Date	Beneficial Conversion Feature Term (months)	Number of shares		Fair Value of Beneficial Conversion Feature		Amount accreted as a deemed dividend at December 31, 2017			Amount accreted as a deemed dividend for the Six Months Ended June 30, 2018			Unamortized Beneficial Conversion Feature
May 17, 2017	12		7,318,084	$	25,247,098	$	(15,779,436	)	$	(9,467,661	)	$	-
July 29, 2017	9.5		1,680,000		6,804,000		(3,674,634	)		(3,129,366	)		-
August 29, 2017	8.5		369,756		1,148,263		(556,190	)		(592,073	)		-
September 15, 2017	8		462,195		1,435,329		(648,601	)		(786,728	)		-
October 11, 2017	7		462,195		1,121,036		(426,309	)		(694,727	)		-
October 31, 2017	6.5		1,042,337		1,735,641		(548,570	)		(1,187,071	)		-
December 19, 2017	5		2,449,634		6,921,348		(576,780	)		(6,344,568	)		-
Total			13,784,201	$	44,412,715	$	(22,210,520	)	$	(22,202,194	)	$	-

For the Nine Months Ended September 30, 2018
Issuance Date Beneficial Conversion Feature Term (months) Number of shares Fair Value of Beneficial Conversion Feature Amount accreted as a deemed dividend at December 31, 2017 Amount accreted as a deemed dividend for the Nine Months Ended September 30, 2018 Unamortized Beneficial Conversion Feature
May 17, 2017 12 7,318,084 $ 25,247,098 $ (15,779,436 ) $ (9,467,661 ) $ -
July 29, 2017 9.5 1,680,000 6,804,000 (3,674,634 ) (3,129,366 ) -
August 29, 2017 8.5 369,756 1,148,263 (556,190 ) (592,073 ) -
September 15, 2017 8 462,195 1,435,329 (648,601 ) (786,728 ) -
October 11, 2017 7 462,195 1,121,036 (426,309 ) (694,727 ) -
October 31, 2017 6.5 1,042,337 1,735,641 (548,570 ) (1,187,071 ) -
December 19, 2017 5 2,449,634 6,921,347 (576,779 ) (6,344,568 ) -
Total 13,784,201 $ 44,412,714 $ (22,210,519 ) $ (22,202,194 ) $ -

Dividends, Voting Rights and Liquidity Value:

Pursuant to the Certificate of Designations, the Series B Preferred Shares shall bear no dividends, except that if the Board shall declare a dividend payable upon the then-outstanding shares of the Company’s common stock. The Series B Preferred Shares vote together with the common stock and all other classes and series of stock of the Company as a single class on all actions to be taken by the stockholders of the Company including, but not limited to, actions amending the certificate of incorporation of the Company to increase the number of authorized shares of the common stock. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series B Preferred Shares are entitled to (i) first receive distributions out of our assets in an amount per share equal to the Stated Value plus all accrued and unpaid dividends, whether capital or surplus before any distributions shall be made on any shares of common stock and (ii) second, on an as-converted basis alongside the common stock.

Classification:

These Series B Preferred Shares are classified within permanent equity on the Company’s consolidated balance sheet as they do not meet the criteria that would require presentation outside of permanent equity under ASC 480,Distinguishing Liabilities from Equity.

~~17.~~14.

Stock Options

On March 15, 2018 the Company awarded Zachary Venegas two options to purchase a total of 490,000 shares of the Company’s common stock at prices ranging from $1.90 to $2.09 per share. These options vested on June 28, 2018 and have expiration dates ranging from March 2023 to March 2028.

As part of the Membership Interest Purchase Agreement entered into between the Company and Security Grade, on June 2, 2017 (see Note 6)5), the Company granted to the selling Members the option to purchase up to 414,854 shares of the Company’s common stock at a price of $0.001 per share. Of the 414,854 options granted, 207,427 were vested at closing and equity classified. The vesting of the remaining 207,427 shares were subject to certain milestones being achieved and was initially recognized as contingent consideration, both a component of purchase price. As a result of the milestones being met during the third quarter of 2017, the remaining 207,427 shares have also vested. The options have an expiration date of 36 months from the closing date. The exercise price will be based on the fair market value of the share on the date of grant.

On March 6, 2018, the Company filed a lawsuit in the United States Court for the District of Colorado alleging violations in previously disclosed representations and warranties by the plaintiff as part of the Acquisition. Following the appointment of a registered Public Company Accounting Oversight Board (“PCAOB”) auditor, certain misrepresentations, primarily surrounding the misclassification of certain revenues as being recurring, were discovered, artificially inflating the price of the membership interest in Security Grade. As a result of certain settlements with the selling shareholder, as of June 30, 2018, 70,151 options previously issued as part of the acquisition were cancelled. Subsequently, as of December 31, 2018, the remaining settlements with the selling shareholders ~~80,979~~were settled and a total of 79,486 options previously issued as part of the acquisition were cancelled.

~~As part~~On February 6, 2019 the Company awarded an executive an option to purchase a total of 100,000 shares of the ~~Merger Agreement entered into~~Company’s common stock at an exercise price $1.51 per share. These options vested on May 6, 2019 and have an expiration date of February 6, 2024.

On March 19, 2019 the Company awarded the Chief Financial Officer, two options to purchase a total of 300,000 shares of the Company’s common stock at prices ranging from $2.35 to $2.59 per share. These options shall vest over a three-year period from March 2020 to March 2022 and have expiration dates ranging from March 2024 to March 2029.

On March 19, 2019 the Company awarded the Chief Executive Officer, two options to purchase a total of 500,000 shares of the Company’s common stock at prices ranging from $2.35 to $2.59 per share. These options shall vest over a three-year period from March 2020 to March 2022 and have expiration dates ranging from March 2024 to March 2029.

On May 2, 2019, the Company awarded an investor an option to purchase a total of 125,000 shares of the Company’s common stock at an exercise price of $2.03 per share. 62,500 of the options shall vest immediately and 62,500 of the options shall vest on August 2, 2019 provided the marketing agreement between the Company and ~~BioTrackTHC,~~grantee has not been terminated. These options shall expire on May 1, 2024.

In May and June ~~1, 2018 (see Note 6),~~2019, the Company ~~assumed~~awarded five employees, an option to purchase a total of 50,000, 40,000, 50,000, 50,000, and 30,000 shares of the ~~BioTrackTHC Stock Plan, pursuant to which options exercisable~~Company’s common stock at prices ~~between $0.001~~ranging from $1.05 to ~~$1.66~~$2.03 per ~~share for 8,132,410 shares of Company common stock are outstanding so that the BioTrackTHC stockholders will own 48% of the Company on~~share. These options shall vest over a ~~fully diluted basis as of the closing date.~~period ranging from September 2019 to June 2020 and have expiration dates ranging from May 2024 to June 2024.

Stock option activity for the period ended ~~September~~June 30, ~~2018~~2019 is as follows:

Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term
(in years)
Outstanding at January 1, 2018 414,854 $ 0.001 2.42

Granted 490,000 $ 1.92 0.51

Options assumed pursuant to acquisition 8,132,410 $ 0.72 2.17

Forfeited and expired (80,979 ) $ 0.001

Exercised (216,616 ) $ 0.001

Outstanding at September 30, 2018 8,739,669 $ 0.001 2.70

Vested options at September 30, 2018 8,466,285 $ 0.69 2.19

	Shares Underlying Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)
Outstanding at January 1, 2019		8,730,956		$	0.671		2.44
Granted		1,245,000		$	2.106		7.06
Exercised		(188,575	)	$	0.261		1.08
Forfeited and expired
Outstanding at June 30, 2019		9,787,381		$	0.862		2.98
Vested options at June 30, 2019		8,900,021		$	0.749		2.13

~~18.~~15.

~~Warrants~~Warrant Liability

On ~~February 13, 2017,~~March 1, 2019, in connection with the ~~Company entered into a $183,333 Fixed secured Convertible Promissory~~issuance of Note (“Note Five”) with a fourth investor (the “Fourth Investor”). The Fourth Investor provided the Company with $166,666 in cash, which was received by the Company during the period ended March 31, 2017. The additional $16,666 was retained by the Fourth Investor for due diligence and legal bills for the transaction. In conjunction with Note Five,Ten, the Company issued ~~a warrant,~~warrants, of which the value was derived and based off the fair value of Note ~~Five,~~Ten, to the ~~fourth~~ investor to purchase ~~25,000~~160,715 shares of the Company’s common stock at ~~$1.00~~$1.40 per share. Exercise of the purchase rights represented by ~~this Warrant~~the warrant may be made, in whole or in part, at any time or times on or after ~~February 14, 2017~~March 1, 2019 and on or before ~~February 12, 2022,~~March 1, 2024, by delivery to the Company of the Notice of Exercise. ~~On December 11, 2017, the investor exercised their purchase right in a net settlement cashless exercise.~~

The Company determined that the warrants associated with Note Ten are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity. The Company has no plans to consummate a fundamental transaction and does not believe a fundamental transaction is likely to occur during the remaining term of the outstanding warrants. In accordance with ASC 480, the outstanding warrants are recognized as a warrant liability on the balance sheet and are measured at their inception date fair value and subsequently re-measured at each reporting period with changes being recorded as a component of other income in the statement of operations. At inception, March 1, 2019, the fair value of the warrant liability was $355,847 while as of June 30, 2019, the fair value of the warrant liability was $141,404. Accordingly, the Company recorded a change in fair value of the warrant liability of $(257,320) and $(214,443) related to Note Ten for the three and six months ended June 30, 2019, respectively.

On January 10, 2019, the Company entered into an Investment Unit Purchase Agreement (the “First Investment Agreement”) to issue and sell investment units to an investor, in which the investment units consist of one share of the common stock of the Company, and a warrant exercisable for one half share of common stock of the Company at an Exercise Price of $1.25 per share for cash at a price per investment unit of $0.90.

On March 5, 2019, the Company sold an aggregate of 1,255,222 units of the Company’s securities to an investor at a purchase price of $0.90 per unit for total proceeds of $1,129,700. In connection with the ~~issuance of~~First Investment Agreement, the ~~Note Seven,~~investor is entitled to purchase from the Company, ~~issued a warrant (the “Warrant”) to~~at the ~~Purchaser to purchase 150,000 shares of Common Stock pursuant to the terms and provisions thereunder. The Warrant is exercisable~~Exercise Price, at any time within five (5) years of issuance and entitles the Purchaser to purchase 150,000 shares of the Common Stock at an exercise price of the lesser of either i) $1.00 or ii) a 50% discount to the lowest closing bid price thirty (30) trading days immediately preceding conversion, subject to certain adjustments.

~~Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times~~ on or after ~~April 26, 2017 and on or before April 26, 2022, by delivery to~~90 days from the ~~Company of the Notice of Exercise. On December 11, 2017, the investor exercised their purchase right in a net settlement cashless exercise.~~

~~During the nine months ended September 30, 2018, the Company entered into a Graduated Lock-Up Letter to induce the entering into of a consulting agreement in exchange for 50,000~~issuance date, 627,611 shares of the Company’s common stock (the “March Warrant Shares”).

The fair value of the March Warrant Shares at issuance on January 10, 2019 is in excess of the proceeds received, the warrant liability is required to be recorded at fair value with the excess of the fair value over the proceeds received recognized as a loss in earnings. The gross proceeds from the 1,255,222 investment units at $0.90 was $1,129,700. The fair value of the March Warrant Shares at issuance was $1,717,506. The amount to be recognized as a loss in earnings is calculated as follows:

Proceeds from January investment units	$	1,129,700
Par value of common stock issues	$	(1,255	)
Fair value of warrants	$	(1,717,506	)
Loss on issuance of warrants (January 10, 2019 issuance)	$	(589,061	)
Loss on issuance of warrants (March 11, 2019 issuance)	$	(198,148	)
Total loss on issuance of warrants	$	(787,209	)

As of June 30, 2019, the fair value of the warrant liability was $538,847 and the ~~granting~~Company recorded a change in fair value of ~~575,000~~the warrant liability of $(1,046,606) and $(1,178,659) for the three and six months ended June 30, 2019, respectively.

On March 11, 2019, the Company issued warrants to an investment bank to purchase a total of 100,000 restricted shares of the Company’s common stock at a per share purchase price of $0.90. The warrants are exercisable at any time six months after the issuance date within three years of issuance.

The Company determined that the warrants are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity. The Company has no plans to consummate a fundamental transaction and does not believe a fundamental transaction is likely to occur during the remaining term of the outstanding warrants. In accordance with the accounting guidance, the outstanding warrants are recognized as a warrant liability on the condensed consolidated balance sheet and are measured at their inception date fair value and subsequently re-measured at each reporting period with changes being recorded as a component of other income in the condensed consolidated statement of operations. At inception, March 11, 2019, the fair value of the warrant liability was $198,148 while as of June 30, 2019, the fair value of the warrant liability was $82,162. Accordingly, the Company recorded a change in fair value of the warrant liability of $(168,380) and $(115,986) related to the warrants for the ~~purchase~~three and six months ended June 30, 2019, respectively.

On June 14, 2019, the Company entered into another Investment Unit Purchase Agreement (the “Second Investment Agreement”) to issue and sell investment units to an investor (the “investor”), in which the investment units consist of one share of the common stock of the Company, and a warrant exercisable for one half share of common stock of the ~~Company.~~ Company at an exercise price of $1.25 per share for cash at a price per investment unit of $0.90.

On June 24, 2019, the Company sold an aggregate of 166,667 units of the Company’s securities to an investor at a purchase price of $0.90 per unit for total proceeds of $150,000. In connection with the Second Investment Agreement, the investor is entitled to purchase from the Company, at the exercise price, at any time on or after 90 days from the issuance date, 83,333 shares of the Company’s common stock (the “June Warrant Shares”).

The ~~company recognized compensation expense~~gross proceeds from the 166,667 investment units at $0.90 was $150,000. The fair value of ~~$943,000~~the June Warrant Shares at issuance was $83,586 while as of June 30, 2019, the fair value of the warrant liability was $73,073. Accordingly, the Company recorded a change in fair value of the warrant liability of ($10,513) related to the warrants for the three and ~~nine~~six months ended ~~September~~June 30, ~~2018 relating to the granting of the new warrants.~~2019.

A summary of warrant activity is as follows:

For the Nine Months Ended September 30, 2018
Warrant Shares Weighted Average Exercise Price
Balance at January 1, 2018 2,732,073 $ 0.23

Warrants granted 575,000 $ 0.01

Balance at September 30, 2018 3,307,073 $ 0.19

For the Six Months Ended June 30, 2019
	Warrant Shares		Weighted Average Exercise Price
Balance at January 1, 2019		3,418,184	$	0.23

Warrants granted		1,507,374	$	1.23

Balance at June 30, 2019		4,925,558	$	0.55

~~Warrant Obligations~~

In connection with the Series B Preferred Stock Purchase Agreement (See FN 16), the Company is obligated to issue warrants to a third-party to purchase 812,073 shares of common stock at $0.325 per share for services rendered. These warrants have been accounted for as warrant obligations and are recognized as a liability on the unaudited condensed consolidated balance sheets as of September 30, 2018 and December 31, 2017. For the three months ended September 30, 2018 and 2017, the Company recorded a credit and a charge in the change in fair value of the warrant obligations of $136,920 and $531,395, respectively, and is reflected in the unaudited condensed consolidated statements of operations, other income (expense). For the nine months ended September 30, 2018 and 2017, the Company recorded a credit and charge in the change in fair value of the warrant obligations of $1,434,760 and $406,604, respectively, and is reflected in the unaudited condensed consolidated statements of operations, other income (expense). Although the Company issued warrants during the first quarter of 2018, the rights entitled to the third-party holder of the warrants to purchase shares of the Company’s common stock was not exercised. Upon exercising the right to purchase the Company’s common stock by the third-party, the Company will de-recognize the liability for warrant obligations and reclassify the appropriate amount into equity.

The fair value of the Company’s ~~obligation to issue warrants~~warrant liability was calculated using the Black-Scholes model and the following assumptions:

	As of September 30, 2018			As of December 31, 2017			As of May 17, 2017			As of June 30, 2019			As of December 31, 2018
Fair value of company’s common stock	$	1.24		$	3.00		$	3.98		$	1.06		$	0.90
Dividend yield		0	%		0	%		0	%		0	%		0	%
Expected volatility		222.8	%		266.4	%		181.2	%		135% - 140%			175.0	%
Risk Free interest rate		2.88	%		1.98	%		1.42	%		1.72% - 2.56%			2.49	%
Expected life (years)		1.90			2.65			3.00			3.19			1.65
Fair value of financial instruments - warrants	$	994,809		$	2,429,569		$	1,839,133		$	2,199,266		$	896,171

The change in fair value of the financial instruments – warrants is as follows:

Amount
Balance as of January 1, 2018 $ 2,429,569

Change in fair value of liability to issue warrants $ (1,434,760 )

Balance as of September 30, 2018 $ 994,809

	Amount
Balance as of January 1, 2019	$	896,171

Fair value of warrants issued		3,541,240

Change in fair value of liability to issue warrants		(2,238,145	)

Balance as of June 30, 2019	$	2,199,266

Amount
Balance as of July 1, 2018 $ 1,131,729

Change in fair value of liability to issue warrants $ (136,920 )

Balance as of September 30, 2018 $ 994,809

	Amount
Balance as of April 1, 2019	$	5,986,781

Fair value of warrants issued		83,586

Change in fair value of liability to issue warrants		(3,871,101	)

Balance as of June 30, 2019	$	2,199,266

~~19.~~16.

~~2017 Omnibus Incentive Plan~~Stock-Based Compensation

2017 Omnibus Incentive Plan

The Company’s 2017 Omnibus Incentive Plan (the “2017 Plan”) was adopted by our Board of Directors and a majority of our voting ~~security holders~~securities on October 17, 2017. The 2017 Plan permits the granting of incentive stock options, ~~nonstatutory~~non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and dividend equivalent rights to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the 2017 Plan at no less than the fair value of the underlying common stock as of the date of grant. Options granted under the Plan have a maximum term of ten years. Under the Plan, a total of 5,000,000 shares of common stock are reserved for ~~issuance. As~~issuance, of ~~September 30, 2018, there were 1,109,995~~which options to purchase 1,735,000 and 490,000 shares of common stock ~~outstanding~~ and ~~490,000~~764,945 and 514,945 shares of common stock were granted as of June 30, 2019 and December 31, 2018, respectively.

Bio-Tech Medical Software, Inc. 2014 Stock Incentive Plan

On October 22, 2014, BioTrackTHC approved and adopted the BioTrackTHC Stock Plan. The BioTrackTHC Stock Plan set aside and reserved 600,000 shares of BioTrackTHC’s common stock for grant and issuance in accordance with its terms and conditions. Persons eligible to receive awards from the BioTrackTHC Stock Plan include employees (including officers and directors) of BioTrackTHC or its affiliates and consultants who provide significant services to BioTrackTHC or its affiliates (the “Grantees”). The BioTrackTHC Stock Plan permits BioTrackTHC to issue to Grantees qualified and/or non-qualified options to purchase BioTrackTHC’s common stock, restricted common stock, performance units, and performance shares. The term of each award under the BioTrackTHC Stock Plan shall be no more than ten years from the date of grant thereof. BioTrackTHC’s Board of Directors or a committee designated by the Board of Directors is responsible for administration of the BioTrackTHC Stock Plan and has the sole discretion to determine which Grantees will be granted awards and the terms and conditions of the awards granted.

BioTrackTHC Management Awards

On September 1, 2015 and November 1, 2015, BioTrackTHC’s Board approved individual employee option grants (the “Executive Grants”) for three executives (the “Executives”). Pursuant to the Executive Grants, the Executives were each granted stock options ~~were granted under~~to purchase 146,507 shares (totaling 439,521 shares) of BioTrackTHC’s common stock (the “Option”) at an exercise price equal to approximately $7.67. The options vest as to 25% of the ~~2017 Plan.~~shares subject to the Options, one year after the date of grant and then in equal quarterly installments for the three years thereafter, subject to the Executive’s continued employment with BioTrackTHC (see Notes 1 and 5).

2017.

Income Taxes

No provision for U.S. federal or state income taxes has been recorded as the Company has incurred net operating losses since inception. Significant components of the Company’s net deferred income tax assets for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018 consist of income tax loss carryforwards. These amounts are available for carryforward for use in offsetting taxable income of future years through 2035. Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carry-forward period. Utilization of the net operating loss carry-forwards may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. Due to the Company’s history of operating losses, these deferred tax assets arising from the future tax benefits are currently not likely to be realized and are thus reduced to zero by an offsetting valuation allowance. As a result, there is no provision for income taxes.

For the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, the Company has a net operating loss carry forward of approximately ~~$9,825,000~~$15,098,000 and ~~$5,800,000,~~$8,365,000, respectively. Utilization of these net loss carry forwards is subject to the limitations of Internal Revenue Code Section 382. The Company applied a 100% valuation reserve against the deferred tax benefit as the realization of the benefit is not certain.

~~21.~~18.

Commitments and Contingencies

Under Topic 842, operating lease expense is generally recognized evenly on a straight-line basis. The Company has operating leases primarily consisting of facilities with remaining lease terms of one year to five years. The lease term represents the period up to the early termination date unless it is ~~obligated under two operating lease agreements for office facilities~~reasonably certain that the Company will not exercise the early termination option. Certain leases include rental payments that are adjusted periodically based on changes in ~~Colorado, Florida, Washington~~consumer price and ~~Hawaii, which expire in February and March 2021.~~other indices.

~~Rent expense incurred under~~Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company combines the lease and non-lease components in determining the lease liabilities and ROU assets.

Activity related to the Company’s leases was as follows:

	Six Months Ended June 30, 2019
Operating lease expense	$	297,566
Cash paid for amounts included in the measurement of operating lease liabilities	$	150,696
ROU assets obtained in exchange for operating lease obligations	$	1,499,752

The Company’s lease agreements generally do not provide an implicit borrowing rate, therefore an internal incremental borrowing rate is determined based on information available at lease commencement date for purposes of determining the present value of lease payments. The Company used the incremental borrowing rate on December 31, 2018 for all leases that commenced prior to that date.

ROU lease assets and lease liabilities for the Company’s operating leases ~~amount to $133,211~~were recorded in the condensed consolidated balance sheet as follows:

	As of June 30, 2019
Other assets	$	1,293,245

Accounts payable and accrued liabilities	$	410,826
Other long-term liabilities		962,716
Total lease liabilities	$	1,373,542

Weighted average remaining lease term (in years)		3.05
Weighted average discount rate		6.00	%

Future lease payments included in the measurement of lease liabilities on the condensed consolidated balance sheet as of June 30, 2019, for the following five fiscal years and ~~$14,438~~thereafter were as follows:

	As of June 30, 2019
2019 - Remaining		238,684
2020		393,413
2021		248,223
2022		195,144
2023		200,944
Thereafter		205,434
Total future minimum lease payments	$	1,481,842
Less imputed interest		(108,300	)
Total	$	1,373,542

As of June 30, 2019, the Company had additional operating lease obligations for a lease with a future effective date of approximately $600,000. This operating lease will commence during the first quarter of fiscal 2022 with a lease term of three ~~months ended September 30,~~years.

As of December 31, 2018, ~~and 2017, respectively and $217,662 and $55,159~~future minimum lease payments, as defined under the previous lease accounting guidance of ASC Topic 840, under noncancelable operating leases for the ~~nine months ended September 30, 2018~~following five fiscal years and ~~2017, respectively.~~thereafter were as follows:

	Operating leases
2019	$	473,495
2020		420,291
2021		275,223
2022		198,144
2023		199,144
Thereafter		205,135
Total lease payments	$	1,771,432

~~22.~~19.

Segment Results

FASB ASC 280-10-50 requires use of the “management approach” model for segment reporting. The management approach is based on the way a company’s management organized segments within the company for making operating decisions and assessing performance. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision–making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision–making group is composed of the Chief Executive Officer. The Company operates in three segments, Security and guarding, Systems installation and Software.

Asset information by operating segment is not presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company’s unaudited condensed consolidated financial statements.

The following represents selected information for the Company’s reportable segments:

For the Three Months Ended
September 30, For the Nine Months Ended
September 30,

2018
(Revised)
2017 2018 2017

Security and guarding
Revenue $ 1,141,676 $ 1,129,746 $ 3,432,651 $ 2,837,145
Cost of revenue 917,620 814,031 2,458,548 2,192,366
Gross profit 224,056 315,715 974,103 644,779
Total operating expenses 2,536,916 1,039,904 7,279,486 2,186,942
Loss from operations (2,312,860 ) (724,189 ) (6,305,383 ) (1,542,163 )
Total other income/(expense) 58,716 468,832 2,050,109 (6,577,864 )
Total net income (loss) $ (2,254,144 ) $ (255,357 ) $ (4,255,274 ) $ (8,120,027 )

Systems installation
Revenue $ 318,850 $ - $ 454,113 $ -
Cost of revenue 194,013 - 379,046 -
Gross profit 124,837 - 75,067 -
Total operating expenses 49,683 - 134,097 -
Loss from operations 75,154 - (59,030 ) -
Total other income/(expense) 406 - 804 -
Total net income (loss) $ 75,560 $ - $ (58,226 ) $ -

Software
Revenue $ 1,653,195 $ - $ 2,229,337 $ -
Cost of revenue 768,428 - 1,055,122 -
Gross profit 884,767 - 1,174,215 -
Total operating expenses 1,384,542 - 1,806,108 -
Loss from operations (499,775 ) - (631,893 ) -
Total other income/(expense) (93 ) - (84 ) -
Total net income (loss) $ (499,868 ) $ - $ (631,977 ) $ -

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2019			2018			2019			2018
Security and guarding
Revenue	$	1,347,529		$	1,197,201		$	2,552,240		$	2,290,975
Cost of revenue		797,944			1,273,693			1,738,530			2,064,398
Gross margin		549,585			(76,492	)		813,710			226,577
Total operating expenses		1,903,371			2,455,685			3,637,078			5,152,876
Loss from operations		(1,353,786	)		(2,532,177	)		(2,823,368	)		(4,926,299	)
Total other income (expense)		7,265,540			735,239			(979,410	)		2,656,120
Total net income (loss)	$	5,911,754		$	(1,796,938	)	$	(3,802,778	)	$	(2,270,179	)

Systems installation
Revenue	$	174,067		$	100,699		$	202,608		$	135,263
Cost of revenue		337,852			-			499,610			-
Gross margin		(163,785	)		100,699			(297,002	)		135,263
Total operating expenses		154,822			-			187,453			-
Loss from operations		(318,607	)		100,699			(484,455	)		135,263
Total other income		513			-			433			-
Total net (loss) income	$	(318,094	)	$	100,699		$	(484,022	)	$	135,263

Software
Revenue	$	2,377,277		$	576,142		$	4,515,132		$	576,142
Cost of revenue		860,903			286,694			1,683,778			286,694
Gross margin		1,516,374			289,448			2,831,354			289,448
Total operating expenses		2,309,704			421,566			4,585,917			421,566
Loss from operations		(793,330	)		(132,118	)		(1,754,563	)		(132,118	)
Total other income		11,978			9			11,970			9
Total net loss	$	(781,352	)	$	(132,109	)	$	(1,742,593	)	$	(132,109	)

~~23.~~20.

Subsequent Events

~~In October 2018 the Company issued 111,111 shares of restricted common stock at $0.90 per share to an investor per a subscription agreement for total proceeds of $100,000.~~

~~In October 2018 the Company issued 583,333 shares of restricted common stock at $0.90 per share to an investor per a subscription agreement for total proceeds of $524,999.~~

~~In October 2018~~On July 29, 2019, the Company entered into an ~~executive employment agreement with Patrick Vo (the “Executive”) whereas~~unsecured promissory note in the amount of $300,000. The unsecured promissory note has a fixed interest rate of 12% per annum and is due and payable upon the maturity date of January 29, 2020.

In August 2019, the Company ~~wishes to continue to employ the Executive~~paid $25,000 in cash as the Chief Executive Officer of its wholly owned Subsidiary, BioTrack THC. The Company will initially pay the Executive a base salary of $175,000 (“Base Salary”). Commencing with the calendar year 2019, the Executive will be eligible to receive an annual bonus targeted at up to fifty percent (50%) of Executive’s Base Salary plus an option grant to be determined by the Company’s Board of Directors or an applicable compensation committeepart of the ~~Board, subject~~original purchase price of Tan Security pursuant to ~~specific provisions. The Executive will be entitled to such other benefits, and to participate in such benefit plans, as are generally made available to similarly situated employees~~the original terms of the ~~Company from time to time, subject to Company policy and the terms and conditions of any applicable benefit plans.~~Tan Security Acquisition Agreement.

In October 2018 the Company entered into an executive employment agreement with Terrance Ferraro (the “Executive”) whereas the Company wishes to continue to employ the Executive as the Chief Software Architect of its wholly owned Subsidiary, BioTrack THC. The Company will initially pay the Executive a base salary of $175,000 (“Base Salary”). Commencing with the calendar year 2019, the Executive will be eligible to receive an annual bonus targeted at up to fifty percent (50%) of Executive’s Base Salary plus an option grant to be determined by the Company’s Board of Directors or an applicable compensation committee of the Board, subject to specific provisions. The Executive will be entitled to such other benefits, and to participate in such benefit plans, as are generally made available to similarly situated employees of the Company from time to time, subject to Company policy and the terms and conditions of any applicable benefit plans.

~~In October 2018 the Company issued 10,000 shares of free trading shares at $1.02 per share to a shareholder per a corporate stock transfer for total proceeds of $10,200.~~

~~In October 2018 the Company issued an additional 10,000 shares of free trading shares at $1.02 per share to a shareholder per a corporate stock transfer for total proceeds of $10,200.~~

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

The following discussion of our financial condition and results of operations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018 should be read in conjunction with our unaudited condensed consolidated financial statements and the notes to those statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under Item 1A. Risk Factors appearing in our Annual Report on Form ~~10-K/A~~10-K for the year ended December 31, ~~2017,~~2018, as filed on April ~~4, 2018~~1, 2019 with the SEC. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.

Unless expressly indicated or the context requires otherwise, the terms “Helix”, the “Company”, “we”, “us”, and “our” refer to Helix TCS, Inc.

Overview

~~Helix’s~~Helix TCS, Inc. provides critical infrastructure solutions to the legal cannabis industry. Our mission is to provide clients with the ~~most powerful and cutting-edge~~best-in-class critical infrastructure services through a single integrated ~~operating environments in the market, helping~~platform which enables them to ~~better manage~~run their businesses more safely, efficiently, and ~~mitigate risk while they focus on their core business. We accomplish these goals through a unique combination of business, logistics, risk-management,~~profitably. As we increase our platform’s scale and ~~investment skills, delivered through a proprietary software suite~~scope, clients will be able to realize greater cost savings and ~~partnership platform.~~operating advantages.

Our team is composed of former military, law enforcement, and technology professionals with deep experience in security and law enforcement, intelligence, technology design and development, partner relations, data aggregation, venture capital, private equity, risk-management, banking, and finance.

Technology is a cornerstone of Helix’s service offering. Our technology platform ~~allowis~~allows clients to manage their business in a compliant manner with BioTrackTHC’s seed-to-sale software, as well as managing inventory and supply costs through ~~Cannabase, as well as~~Cannabase. We also provide bespoke monitoring and transport solutions. We focus on utilizing technology as an operations multiplier, bringing in and managing unique partnerships across the tech spectrum to tailor and guarantee desired outcomes for our clients.

Within the cannabis industry, no other activity carries as much potential for unforeseen negative impact as a lapse in compliance operations. Helix brings a broad range of compliance services to firms in the cannabis industry, safeguarding their ability to operate while increasing their access to services that offer them a competitive edge.

We have greatly enhanced our core operations with the acquisitions of Security Grade, BioTrackTHC, Engeni and ~~BioTrack.~~Tan Security. Security Grade is a market leader in the security profession and provides a broad range of services, from security consulting to installation ~~and monitoring~~ of surveillance technology. Consistent with our team of professionals, Security Grade employs specialists with extensive experience and exposure to all areas of security related services. ~~BioTrack~~BioTrackTHC specializes in providing cannabis software services, ranging from monitoring of plant inventory to point-of-sale solutions. BioTrackTHC’s software is used by 9 government entities and more than 2,000 commercial client locations across 34 U.S. states and 6 countries. Engeni provides a turnkey and comprehensive digital presence solution for small businesses. The Engeni Growth solution includes an optimized web page, a fully-paid Google pay-per-click campaign, lead capture & lead delivery and ubiquitous directory/map listings. Engeni has also become the Company’s offshore software development platform, and is currently working on the second generation of the BioTrackTHC software. These strategic acquisitions will help field the growing demand in the Legal Cannabis Industry. Tan Security, a licensed security company, provided the Company a platform with which to expand security operations in the state of California.

Results of Operations for the three months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018

The following table shows our results of operations for the three months ended ~~September~~June 30, ~~2018~~2019 and ~~2017.~~2018. The historical results presented below are not necessarily indicative of the results that may be expected for any future period.

	For the Three Months Ended September 30,						Change						For the Three Months Ended June 30,						Change
	2018			2017			Dollars			Percentage			2019			2018			Dollars			Percentage
Revenue	$	3,113,721		$	1,129,746		$	1,983,975			176	%	$	3,898,873		$	1,874,042		$	2,024,831			108	%
Cost of revenue		1,880,061			814,031			389,156			131	%		1,996,699			1,560,387			436,312			28	%
Gross margin		1,233,660			315,715			1,594,819			291	%		1,902,174			313,655			1,588,519			506	%

Operating expenses		3,971,141			1,039,904			2,931,237			282	%		4,367,897			2,877,251			1,490,646			52	%

Loss from operations		(2,737,481	)		(724,189	)		(1,336,418	)		278	%		(2,465,723	)		(2,563,596	)		97,873			-4	%

Other income (expense), net		59,029			468,832			(409,803	)		-87	%		7,278,031			735,248			6,542,783			890	%

Net loss	$	(2,678,452	)	$	(255,357	)	$	(1,746,221	)		949	%
Net income (loss)													$	4,812,308		$	(1,828,348	)	$	6,640,646			-363	%

Changes in foreign currency translation adjustment													$	(590	)	$	-		$	(590	)		100	%

Convertible preferred stock beneficial conversion feature accreted as a deemed dividend		-			(8,044,958	)		8,044,958			-100	%		-			(7,203,689	)		7,203,689			-100	%

Net loss attributable to common shareholders	$	(2,660,914	)	$	(8,300,315	)	$	6,316,275			-68	%
Net income (loss) attributable to common shareholders													$	4,811,718		$	(9,032,037	)	$	13,843,755			-153	%

Revenue

Total revenue for the three-month period ended ~~September~~June 30, ~~2018~~2019 was ~~$3,113,721,~~$3,898,873, which represented an increase of ~~$1,983,975~~$2,024,831 compared to total revenue of ~~$1,129,746~~$1,874,042 for the three months ended ~~September~~June 30, ~~2017.~~2018. The increase primarily resulted from ~~new~~additional revenue ~~streams~~resulting from the BioTrackTHC acquisition and an increase in the number of ~~BioTrackTHC.~~clients serviced by our security operations.

Cost of Revenues

Cost of revenues for the three months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018 primarily consisted of hourly compensation for security ~~personnel.~~personnel and employees involved in the creation and development of licensing software. Cost of revenues increased by ~~$1,066,030~~$436,312 for the three months ended ~~September~~June 30, ~~2018,~~2019, to ~~$1,880,061~~$1,996,699 as compared to ~~$814,031~~$1,560,387 for the three months ended ~~September~~June 30, ~~2017.~~2018. The increase primarily resulted from ~~an increase in personnel associated with~~ the acquisition of ~~BioTrackTHC.~~BioTrackTHC and a substantial increase in the number of clients serviced by Helix security, which required the hiring of additional employees.

Operating Expenses

Our operating expenses encompass selling, general and administrative expenses, salaries and wages, professional and legal fees and depreciation. Selling, general and administrative expenses consist primarily of rent/moving expenses, advertising and travel expenses. Salaries and wages is composed of non-revenue generating employees. Professional services are principally comprised of outside legal, audit, information technology consulting, marketing and outsourcing services as well as the costs related to being a publicly traded company. Our operating expenses during the three months ended ~~September~~June 30, 2019 and 2018 were $4,367,897 and ~~2017 were $3,971,141 and $1,039,904~~$2,877,251, respectively. The overall ~~$2,931,237~~$1,490,646 increase in operating expenses was attributable to the following ~~increases~~increases/(decreases) in operating expenses of:

	●	Selling, general and administrative – ~~$533,581~~$642,492

	●	Salaries and wages – ~~$1,572,839~~$(1,113)

	●	Professional and legal fees – ~~$212,533~~$523,306

	●	Depreciation and amortization – ~~$612,264~~$325,961

The ~~$533,581~~$642,492 increase in selling, general and administrative expenses is a result of increases in rent expense, advertising and travel expenses resulting from an expansion in our operations. The ~~$1,572,839 increase~~$1,113 decrease in salaries and wages resulted from ~~an increase~~a decrease in ~~headcount, including BioTrack and Engeni personnel and an increase in share-based compensation.~~stock compensation expense. The ~~$212,533~~$523,306 increase in professional and legal fees primarily resulted from an increase in legal fees and costs associated with fundraising. The ~~$612,264~~$325,961 increase in depreciation and amortization was due to amortization of intangible assets acquired in the ~~BioTrack~~BioTrackTHC and Engeni acquisitions.

Other Income (Expense), net

Other income (expense)

~~Net other income (expense)~~, net consisted of a change in the fair value of convertible notes, change in the fair value of convertible notes – related party, change in fair value of warrant ~~obligations,~~liability, change in fair value of contingent consideration, gain on reduction of obligation pursuant to acquisition and interest (expense) income. Other income (expense)~~. Net other income (expense)~~, net during the three months ended ~~September~~June 30, 2019 and 2018 was $7,278,031 and ~~2017 was $59,029 and $468,832,~~$735,248, respectively. The ~~$409,802 decrease~~$6,542,783 increase in other income (expense), net was primarily attributable to a ~~loss~~gain on the change in fair value of convertible notes of ~~$(17,880),~~$845,622, gain ~~on the change in the fair value of warrant obligations of $136,920, loss~~ on the change in fair value of ~~contingent consideration~~convertible notes – related party of ~~$(131,994) and~~$2,818,739, gain on the change in fair value of warrant liability of $3,871,101, partially offset by interest ~~income~~expense of ~~$21,622 recognized in~~$514,081 during the three months ended ~~September~~June 30, ~~2018.~~2019.

Net ~~loss~~income (loss)

For the foregoing reasons, we had a net ~~loss~~income of ~~$2,678,452~~$4,812,308 for the three months ended ~~September~~June 30, 2019, or $0.06 per basic share, compared to a net loss of $1,828,348 for the three months ended June 30, 2018, or $0.04 net loss per common share ~~basic and diluted, respectively compared to a net loss of $255,357 for the three months ended September 30, 2017, or $0.29 net loss per common share,~~– basic and diluted.

Convertible preferred stock beneficial conversion feature accreted as a deemed dividend

The convertible preferred stock beneficial conversion feature accreted as a deemed dividend resulted from the effective conversion price of the Series B preferred shares at issuance being less than the fair value of the common stock into which the preferred shares are convertible. The result was a non-cash charge in the amount of $0 for the three months ended ~~September~~June 30, ~~2018~~2019 compared to ~~$8,044,958~~$7,203,689 for the three months ended ~~September~~June 30, ~~2017~~2018.

Net ~~Loss~~income (loss) Attributable to common shareholders

For the foregoing reasons, we had a net ~~loss~~gain attributable to common shareholders of ~~$2,660,914~~$4,811,718 for the three months ended ~~September~~June 30, ~~2018,~~2019, or ~~$0.04 net loss~~$.06 per basic share attributable to common shareholders, ~~- basic and diluted,~~ compared to net loss attributable to common shareholders of ~~$8,300,315~~$9,032,037 for the three months ended ~~September~~June 30, ~~2017,~~2018, or ~~$0.29~~$0.21 net loss per share attributable to common shareholders – basic and diluted.

Results of Operations for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018

The following table shows our results of operations for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017.~~2018. The historical results presented below are not necessarily indicative of the results that may be expected for any future period.

	For the Nine Months Ended September 30,						Change						For the Six Months Ended June 30,						Change
	2018			2017			Dollars			Percentage			2019			2018			Dollars			Percentage
Revenue	$	6,116,101		$	2,837,145		$	3,278,956			116	%	$	7,269,980		$	3,002,380		$	4,267,600			142	%
Cost of revenue		3,892,716			2,192,366			1,700,350			78	%		3,921,918			2,351,092			1,570,826			67	%
Gross margin		2,223,385			644,779			1,578,606			245	%		3,348,062			651,288			2,696,774			414	%

Operating expenses		9,219,691			2,186,942			7,032,749			322	%		8,410,448			5,574,442			2,836,006			51	%

Loss from operations		(6,996,306	)		(1,542,163	)		(5,454,143	)		354	%		(5,062,386	)		(4,923,154	)		(139,232	)		3	%

Other income (expense), net		2,050,829			(6,577,864	)		8,628,693			-131	%		(967,007	)		2,656,129			(3,623,136	)		-136	%

Net loss	$	(4,945,477	)	$	(8,120,027	)	$	3,174,550			-39	%	$	(6,029,393	)	$	(2,267,025	)	$	(3,762,368	)		166	%

Changes in foreign currency translation adjustment													$	3,657		$	-		$	3,657			100	%

Convertible preferred stock beneficial conversion feature accreted as a deemed dividend		(22,202,194	)		(11,200,845	)		(11,001,349	)		98	%		-			(22,202,194	)		22,202,194			-100	%

Net loss attributable to common shareholders	$	(27,130,133	)	$	(19,320,872	)	$	(7,809,261	)		40	%	$	(6,025,736	)	$	(24,469,219	)	$	18,443,483			-75	%

Revenue

Total revenue for the ~~nine-month~~six-month period ended ~~September~~June 30, ~~2018~~2019 was ~~$6,116,101,~~$7,269,980, which represented an increase of ~~$3,278,956~~$4,267,600 compared to total revenue of ~~$2,837,145~~$3,002,380 for the ~~nine~~six months ended ~~September~~June 30, ~~2017.~~2018. The increase primarily resulted from ~~increased~~additional revenue resulting from the BioTrackTHC acquisition and an increase in the number of clients serviced by our security ~~and guarding, and new revenue streams of systems installations and software.~~operations.

Cost of Revenues

Cost of revenues for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018 primarily consisted of hourly compensation for security ~~personnel.~~personnel and employees involved in the creation and development of licensing software. Cost of revenues increased by ~~$1,700,350~~$1,570,826 for the ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, to ~~$3,892,716~~$3,921,918 as compared to ~~$2,192,366~~$2,351,092 for the ~~nine~~six months ended ~~September~~June 30, ~~2017.~~2018. The increase primarily resulted from ~~an increase in security personnel associated with higher revenue, as well as~~ the acquisition of ~~BioTrack.~~BioTrackTHC and a substantial increase in the number of clients serviced by Helix security, which required the hiring of additional employees.

Operating Expenses

Our operating expenses encompass selling, general and administrative expenses, salaries and wages, professional and legal fees and ~~depreciation and amortization.~~depreciation. Selling, general and administrative expenses consist primarily of rent/moving expenses, advertising and travel expenses. Salaries and wages is composed of non-revenue generating employees. Professional services are principally comprised of outside legal, audit, information technology consulting, marketing and outsourcing services as well as the costs related to being a publicly traded company. Our operating expenses during the ~~nine~~six months ended ~~September~~June 30, 2019 and 2018 were $8,410,448 and ~~2017 were $9,219,691 and $2,186,942~~$5,574,442, respectively. The overall ~~$7,032,749~~$2,836,006 increase in operating expenses was attributable to the following increases in operating expenses of:

	●	Selling, general and administrative – ~~$1,028,630~~$1,231,490

	●	Salaries and wages – ~~$3,706,740~~$384,144

	●	Professional and legal fees – ~~$720,247~~$592,002

	●	Depreciation and amortization – ~~$1,577,132~~$1,292,699

The ~~$1,028,630~~$1,231,490 increase in selling, general and administrative expenses is a result of increases in rent expense, advertising and travel expenses resulting from an expansion in our operations. The ~~$3,706,740~~$384,144 increase in salaries and wages resulted from ana significant increase in headcount, including ~~BioTrack~~BioTrackTHC and Engeni ~~personnel and an increase in share-based compensation.~~personnel. The ~~$720,247~~$592,002 increase in professional and legal fees primarily resulted from an increase in legal fees and costs associated with ~~obtaining capital resources.~~fundraising. The ~~$1,577,132~~$1,292,699 increase in depreciation and amortization was due to amortization of intangible assets acquired in the ~~BioTrack~~BioTrackTHC and Engeni acquisitions.

Other Income (Expense), net

Other income (expense)

~~Net other income (expense)~~, net consisted of a change in the fair value of convertible ~~note,~~notes, change in the fair value of convertible notes – related party, change in fair value of warrant ~~obligations, change in the fair value of note payable – related party,~~liability, change in fair value of contingent consideration, loss on ~~induced conversion~~issuance of ~~convertible note, loss on extinguishment of debt, loss on impairment of goodwill,~~warrants, gain on reduction of obligation pursuant to acquisition and interest (expense) income. Other income (expense)~~. Net other income (expense)~~, net during the ~~nine~~six months ended ~~September~~June 30, 2019 and 2018 was ($967,007) and ~~2017 was $2,050,829 and $(6,577,864),~~$2,656,129, respectively. The ~~$8,628,693 increase~~$3,623,136 decrease in other income (expense), net was primarily attributable to a ~~gain~~loss on the change in fair value of convertible notes of ~~$679,766,~~$142,341, loss on the change in fair value of convertible notes – related party of $705,270, loss on the change in fair value of contingent consideration of $880,050, loss on issuance of warrants of $787,209, and interest expense of $690,282, partially offset by a gain on the change in ~~the~~ fair value of warrant ~~obligations~~liability of ~~$1,434,760, interest income of $6,705 and no loss on induced conversion of convertible note or loss on extinguishment of debt for~~$2,238,145, during the ~~nine~~six months ended ~~September~~June 30, ~~2018.~~2019.

Net ~~loss~~income (loss)

For the foregoing reasons, we had a net loss of ~~$4,945,477~~$6,029,393 for the ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, or ~~$0.57~~$0.08 net loss per common share – basic and diluted, ~~respectively~~ compared to a net loss of ~~$8,120,027~~$2,267,025 for the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, or ~~$0.68~~$0.06 net loss per common share – basic and diluted.

Convertible preferred stock beneficial conversion feature accreted as a deemed dividend

The convertible preferred stock beneficial conversion feature accreted as a deemed dividend resulted from the effective conversion price of the Series B preferred shares at issuance being less than the fair value of the common stock into which the preferred shares are convertible. The result was a non-cash charge in the amount of $0 for the six months ended June 30, 2019 compared to $22,202,194 for the ~~nine~~six months ended ~~September~~June 30, ~~2018 compared to $11,200,845 for the nine months ended September 30, 2017.~~2018.

Net ~~Loss~~income (loss) Attributable to common shareholders

For the foregoing reasons, we had a net loss attributable to common shareholders of ~~$27,130,133~~$6,025,736 for the ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, or ~~$.57~~$.08 net loss per share attributable to common shareholders - basic and diluted, compared to net loss attributable to common shareholders of ~~$19,320,872~~$24,469,219 for the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2018, or $0.68 net loss per share attributable to common shareholders – basic and diluted.

Liquidity, Capital Resources and Cash Flows

Going Concern

Management believes that we will continue to incur losses for the immediate future. Therefore, we may either need additional equity or debt financing until we can achieve profitability and positive cash flows from operating activities, if ever. These conditions raise substantial doubt about our ability to continue as a going concern. Our condensed consolidated financial statements do not include any adjustments relating to the recovery of assets or the classification of liabilities that may be necessary should we be unable to continue as a going concern. For the ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, we have generated revenue and are trying to achieve positive cash flows from operations.

The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business.

As of ~~September~~June 30, ~~2018,~~2019, we had a cash balance of ~~$464,992, net~~$800,015, accounts receivable, net of ~~$1,152,337~~$1,640,996 and ~~$3,929,203~~$6,708,392 in current liabilities. At the current cash consumption rate, we may need to consider additional funding sources toward the end of fiscal ~~2018.~~2019. We are taking proactive measures to reduce operating expenses, ~~and~~ drive growth in ~~revenue.~~revenue and expeditiously resolve any remaining legal matters.

The successful outcome of future activities cannot be determined at this time and there is no assurance that, if achieved, we will have sufficient funds to execute our intended business plan or generate positive operating results.

The condensed consolidated financial statements do not include any adjustments related to this uncertainty and as to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should we be unable to continue as a going concern.

Capital Resources

The following table summarizes total current assets, liabilities and working capital for the periods indicated:

	September 30, 2018			December 31, 2017			Change			June 30, 2019			December 31, 2018			Change
Current assets	$	1,642,121		$	1,519,714		$	122,407		$	2,993,370		$	1,923,353		$	1,070,017
Current liabilities		3,929,203			4,808,995			(879,792	)		6,708,392			4,157,005			2,551,387
Working Capital	$	(2,287,082	)	$	(3,289,281	)	$	1,002,199
Working capital										$	(3,715,022	)	$	(2,233,652	)	$	(1,481,370	)

As of ~~September~~June 30, ~~2018,~~2019, and December 31, ~~2017,~~2018, we had a cash balance of ~~$464,992~~$800,015 and ~~$868,554,~~$285,761, respectively.

Summary of Cash ~~Flows.~~Flows

	For the Nine Months Ended September 30,						For the Six Months Ended June 30,
	2018			2017			2019			2018

Net cash used in operating activities	$	(3,217,350	)	$	(1,452,666	)	$	(1,889,854	)	$	(1,623,613	)
Net cash provided by (used in) investing activities		230,248			(1,709,239	)
Net cash used in investing activities								(647,014	)		(94,871	)
Net cash provided by financing activities		2,641,985			3,234,189			3,099,741			1,294,457

Net cash used in operating ~~activities~~.activities.Net cash used in operating activities for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 was ~~$(3,217,350)~~$(1,889,854). This included a net loss of ~~$(4,945,477)~~$6,029,393, non-cash charge related to depreciation and amortization of $2,355,977, non-cash charge related to amortization of debt discounts of $519,472, non-cash charge from loss on issuance of warrants of $787,209, non-cash charge related to provision for doubtful account $104,288, non-cash charge related to share-based compensation of $889,400, non-cash losses (gains) due to changes in fair value of convertible notes, fair value of convertible notes – related party, fair value of warrant liability, fair value of contingent consideration of $142,341, $705,270, $(2,238,145) and $880,050, non-cash gains on reduction of contingent consideration of $100,000, and changes in accounts receivable, deposits, costs in excess of billings, billings in excess of costs, deferred rent, accounts payable and accrued expenses, prepaid expenses, due from related party, and right of use assets and liabilities of $93,677. Net cash used in operating activities for the six months ended June 30, 2018 was $(1,623,613). This included a net loss of $(2,267,025), non-cash charge related to depreciation and amortization of ~~$1,869,889,~~$1,063,278, non-cash charge related to share-based compensation of ~~$2,143,548,~~$1,619,753, non-cash ~~losses~~gains due to changes in fair value of convertible notes, fair value of warrant obligations, and fair value of a related party note of ~~$(504,768)~~$(522,646), ~~$(1,434,760)~~$(1,297,840), and ~~$(93,506)~~$(118,506), respectively, ~~non-cash gain on change in fair value of contingent consideration of $131,994,~~ non-cash charge from loss on impairment of goodwill of $664,329, non-cash gain on reduction of obligation pursuant to acquisition of ~~$607,415,~~$(557,054), and changes in accounts receivable, deposits, costs in excess of billings, billings in excess of costs, deferred rent, and accounts payable and accrued expenses of ~~$(441,184)~~$(207,902).

Net cash used in operating activities for the nine months ended September 30, 2017 was $1,452,666. This included a net loss of $8,120,027, non-cash charge related to depreciation and amortization of $292,757, non-cash loss of $210,000 regarding the change in fair value of convertible notes, non-cash gain of $8,971 regarding the fair value of convertible notes – related party, non-cash gain of $10,186 regarding the change in fair value of contingent consideration, non-cash loss on beneficial conversion feature of $390,666, non-cash loss on extinguishment of debt of $4,611,395, non-cash loss on induced conversion of convertible note of $1,503,876, non-cash gain on the change in fair value of warrants to be issued of $406,604 and changes in accounts receivable, deposits, accounts payable, accrued expenses and deferred rent of $160,415.

~~Net cash provided by (used in)~~ investing activities. Net cash provided by investing activities for the nine months ended September 30, 2018 was $230,248, which consisted of capital expenditures of $85,665, cash payments pursuant to the Revolutionary asset acquisition of $58,729, payments pursuant to the Security Grade business acquisition of $79,664, and cash acquired as part of the BioTrack business combination and Engeni business acquisition in the amount of $454,306.Net cash used in investing activities for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2019 was ~~$1,709,239,~~$(647,014), which consisted of capital expenditures of ~~$31,054,~~$(505,904), purchase of domain names of $(17,383) and payments pursuant to the Tan Security business acquisition and Security Grade business acquisition of $(123,727). Net cash ~~payments~~used in investing activities for the six months ended June 30, 2018 was $(94,871), which consisted of capital expenditures of $(484,838), cash payment pursuant to the Revolutionary asset acquisition of ~~$46,872~~$(58,730), and payments as part of the ~~Security Grade~~BioTrackTHC business ~~acquisition~~combination, net of ~~$1,631,313.~~cash acquired in the amount of $448,697.

Net cash provided by financing activities.Net cash provided by financing activities for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 was ~~$2,641,985,~~$3,099,741, which resulted from ~~payments pursuant to convertible notes payable – related party of $150,000, proceeds from notes payable of $16,271, proceeds from the~~ issuance of a promissory note receivable of ~~$250,000,~~$(75,000), repayment of notes payable of $(11,322), proceeds and repayment of a promissory note of $(280,000), proceeds from the issuance of common stock of ~~$2,595,214~~$1,306,313, proceeds from the issuance of convertible note payable of $1,925,000 and repayment of advances from related parties of ~~$69,500.~~$(45,250). Net cash provided by financing activities for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2018 was ~~$3,234,189,~~$1,294,457, which resulted from proceeds from the issuance of ~~convertible~~common stock of $1,320,212, proceeds from notes payable of ~~$229,167, proceeds~~$33,745, and repayment of $255,000 from the issuance of promissory notes and advances from shareholders of $60,500, proceeds from the issuance of common stock of $100,000, proceeds from the issuance of Series B convertible preferred stock of $2,624,988, payments pursuant to advances from related parties of ~~$32,000 and payments pursuant to notes payable of $3,466.~~ $(59,500).

Off-Balance Sheet Arrangements

None.

Critical Accounting Policies and Estimates

Critical accounting policies and estimates are further discussed in our Annual Report on Form ~~10-K/A~~10-K for the year ended December 31, ~~2017~~2018 filed with the SEC on April ~~4, 2018.~~

1, 2019.

Related Party Transactions

In March 2016, the Company issued 960,000 shares of restricted common stock to the Related Party Holder per a subscription agreement for total proceeds of $150,000. In conjunction with the subscription agreement, the Company issued a warrant to the Related Party Holder to purchase 1,920,000 restricted shares of the Company’s common stock at $0.16 per share. The Warrant Exercise Date is the later of the following to occur (i) March 9, 2017, (ii) ten (10) days after the Company’s notice to the holder of the warrant that the Company shall have an effective S-1 registration with the SEC; or (iii) ten (10) days after Company’s notice to the holder of the warrants that the Company has entered into an agreement for the sale of substantially all the assets or Common Stock of the Company. As of June 30, 2019, the warrants granted are not exercisable.

~~The~~2018 (the “Maturity Date”). Note ~~is hereby~~Eight was amended as follows. The Company promises to pay (i) all accrued interest on the unpaid principal amount through December 31, 2017 and (ii) $25,000 in principal within 5 business days of the date of ~~this~~the Amendment. The Company agrees to issue 15,000 shares of restricted Company common stock as an inducement for ~~this amendment~~the Amendment within 10 business days of the date of ~~this~~the Amendment. The principal amount of the ~~note~~Note Eight will be reduced to $125,000. Unless extended by the Company, converted or prepaid earlier, all unpaid principal and unpaid accrued interest on ~~this~~ Note shall be due and payable on ~~August 20, 2018 (the “Maturity Date”).~~the Maturity Date. All provisions related to conversion of ~~the~~ Note Eight into equity securities of the Company were terminated as part of ~~this~~the Amendment.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable for a smaller reporting company.

ITEM 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) ~~and15d-15(e)~~and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (who is our Principal Executive Officer) and our Chief Financial Officer (who is our Principal Financial Officer), to allow timely decisions regarding required disclosures. Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control problems or acts of fraud, if any, within the Company have been detected.

These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer has concluded that as of ~~September~~June 30, ~~2018,~~2019, our disclosure controls and procedures were effective.

Management’s Report on Internal Controls Over Financial Reporting

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our ~~disclosure~~internal controls ~~and procedures~~over financial reporting as of ~~September~~June 30, ~~2018,~~2019, the end of the interim period covered by this report established inInternal Control – Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013. The evaluation of our ~~disclosure~~internal controls ~~and procedures~~over financial reporting included a review of the ~~disclosure controls’ and procedures’~~internal control objectives, design, implementation and the effect of the controls and procedures on the information generated for use in this report.

In the course of our evaluation, we sought to identify errors, control problems or acts of fraud and to confirm the appropriate corrective actions, including process improvements, were being undertaken. Based on that evaluation, management, including our Chief Executive Officer and Chief Financial Officer, concluded that the Company did not maintain effective internal control over financial reporting as of the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 due to the existence of material weaknesses in the internal control over financial reporting described below.

A material weakness is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Management has determined that we did not maintain effective internal controls over financial reporting as of ~~September~~June 30, ~~2018~~2019 due to the existence of the following material weaknesses identified by management:

●

The Company did not maintain effective controls over certain aspects of the financial reporting process because we lacked personnel with accounting expertise and an adequate supervisory review structure that is commensurate with our financial reporting requirements.

●

Inadequate segregation of duties.

We expect to be materially dependent on a third party that can provide us with accounting consulting services for the foreseeable future. We believe that we are in the process of addressing the deficiencies that affected our internal control over financial reporting and we are developing specific action plans for each of the above material weaknesses. Because the remedial actions require hiring of additional personnel, upgrading certain of our information technology systems and relying extensively on manual review and approval, the successful operation of these controls for at least several quarters may be required before management may be able to conclude that the material weaknesses have been remediated. We intend to continue to evaluate and strengthen our internal control over financial reporting. These efforts require significant time and resources. If we are unable to establish adequate internal control over financial reporting, we may encounter difficulties in the audit or review of our financial statements by our independent registered public accounting firm, which in turn may have a material adverse effect on our ability to prepare financial statements in accordance with GAAP and to comply with our SEC reporting obligations.

This quarterly report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting because we are a “smaller reporting company.” Our management’s report was not subject to attestation by our independent registered public accounting firm pursuant to rules of the SEC that permit us to provide only management’s report in this quarterly report.

Changes in internal control over financial reporting

During the ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, there was no change in our internal control over financial reporting or in other factors that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. Legal Proceedings

Occasionally, we may be involved in claims and legal proceedings arising from the ordinary course of our business. We record a provision for a liability when we believe that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on our consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.

There is currently no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self- regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our Company’s subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material effect on the Company, with the exception of:

Baker, et al. v. Helix TCS, Inc.

On March 8, 2017, two former employees filed a lawsuit in the United States District Court for the District of Colorado alleging violations of the Fair Labor Standards Act and the Colorado Wage Act on behalf of themselves and other employees. The plaintiffs seek damages for our alleged failure to compensate them appropriately for the overtime hours they worked as purported “non-exempt” employees. ~~On April 3, 2017, we moved to dismiss the complaint.~~ As of ~~September~~June 30, ~~2018,~~2019, the claim is currently pending the outcome of certain matters in the ~~process of discovery.~~Kenney, et al v. Helix TCS, Inc. case.

Kenney, et al. v. Helix TCS, Inc.

On July 20, 2017 one former employee filed a lawsuit in the United States District Court for the District of Colorado alleging violations of the Fair Labor Standards Act on behalf of themselves and other employees. The plaintiffs seek damages for our alleged failure to compensate them appropriately for the overtime hours they worked as purported “non-exempt” employees. As of June 30, 2019, the claim is currently in the process of discovery.

At this time, the Company is not able to predict the outcome of the ~~lawsuit,~~lawsuits, any possible loss or possible range of loss associated with the ~~lawsuit~~lawsuits or any potential effect on the Company’s business, results of operations or financial condition. However, the Company believes the ~~lawsuit is~~lawsuits are wholly without merit and will defend itself from these claims vigorously.

~~Helix TCS, Inc. v. Beckett, et al.~~

On March 6, 2018 the Company filed a lawsuit in the District Court for the city and county of Denver alleging violations in previously disclosed representations and warranties by the plaintiff as part of the Security Grade acquisition. Following the appointment of a registered Pubic Company Accounting Oversight Board (“PCAOB”) auditor, certain financial misrepresentations, including undisclosed liabilities, the overstatement of revenues, and the misclassification of certain revenues as being recurring, were discovered, ultimately artificially inflating the price of the membership interests in Security Grade. All matters related to the acquisition of Security Grade have been settled as of September 30, 2018.

ITEM 1A. Risk Factors

Smaller reporting companies such as us are not required to provide the information required by this item.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

~~On August 3, 2018,~~During the ~~Company~~six months ended June 30, 2019, we issued ~~366,700~~3,086,893 shares of ~~Company~~ common stock ~~to Engeni US members in connection~~ with the closing of the Engeni Merger Agreement. With the exception of the aforementioned issuance of shares, there were no unregistered sales of equity securities for the quarter ended September 30, 2018 that were not otherwise disclosed or required to be reported on a Current Report on Form 8-K.proceeds received totaling $1,306,313.

ITEM 3. Defaults upon Senior Securities

None.

ITEM 4. Mine Safety Disclosure

Not applicable.

ITEM 5. Other Information

None.

4151

ITEM 6. Exhibits

Exhibit No.		Description

10.43		Form of Management Consulting Services Agreement by and between the Company and Rose Management Group LLC (incorporated by reference to Exhibit 10.43 of the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on April 18, 2019).

31.1		Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)). *

31.2		Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)). *

32.1		Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *

32.2		Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *

101.INS		XBRL Instance Document *

101.SCH		XBRL Taxonomy Extension Schema *

101.CAL		XBRL Taxonomy Extension Calculation Linkbase *

101.DEF		XBRL Taxonomy Extension Definition Linkbase *

101.LAB		XBRL Taxonomy Extension Label Linkbase *

101.PRE		XBRL Taxonomy Extension Presentation Linkbase *

Filed herewith

Management contract or compensatory plan.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: ~~November 15, 2018~~

By:

/s/Zachary L. Venegas

Zachary L. Venegas

Chief Executive Officer

(Principal Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date

/s/Zachary L. Venegas	Chief Executive Officer	~~November 15, 2018~~August 14, 2019
Zachary L. ~~Venegas~~Venegas*	(Principal Executive Officer)


/s/Scott Ogur	Chief Financial Officer	~~November 15, 2018~~August 14, 2019
Scott Ogur	(Principal Financial Officer)

/s/Paul Hodges	Director	August 14, 2019
Paul Hodges*

/s/Patrick Vo	Director	August 14, 2019
Patrick Vo*

/s/Terence Ferraro	Director	August 14, 2019
Terence Ferraro*

/s/Andrew Schweibold	Director	August 14, 2019
Andrew Schweibold*

/s/Satyavrat Joshi	Director	August 14, 2019
Satyavrat Joshi*

* By:

Scott Ogur, as Attorney in Fact, pursuant to the
Power of Attorney dated August 14, 2019 and filed herewith.

4353

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		HLIX		OTCQB

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐☒	Smaller reporting company	☒
		Emerging growth company	☐

	Common Stock				Preferred Stock (Class A)				Preferred Stock (Class B)				Additional Paid-In			Accumulated Other Comprehensive		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Shares		Amount		Capital			Income		Deficit			Equity
Balance at December 31, 2017		28,771,402	$	28,771		1,000,000	$	1,000		13,784,201	$	13,784	$	18,741,114		$	-	$	(18,241,708	)		542,961

Beneficial conversion feature of Series B convertible preferred stock														22,202,194								22,202,194

Deemed dividend on conversion of Series B convertible preferred stock to common stock														(22,202,194	)							(22,202,194	)

Issuance of common stock per stock subscription agreements		2,883,331		2,883										2,592,114								2,594,997

Issuance of common stock resulting from convertible note conversion		205,974		206										174,794								175,000

Issuance of restricted common stock		157,850		158										452,821								452,979

Reduction in Additional Paid-In Cap ital due to Security Grade acquisition settlement agreement														(340,039	)							(340,039	)

Restricted common stock issued as part of BioTrack acquisition		38,184,985		38,185										57,513,848								57,552,033

Restricted common stock issued as part of Engeni acquisition		366,700		367										388,335								388,702

Issuance of common stock to employees under Stock Incentive Plan		227,095		227										308,842								309,069

Issuance of common stock resulting from inducement of consulting agreement		250,000		250										336,250								336,500

Issuance of restricted common stock resulting from an investor relation consulting agreement		100,000		100										101,900								102,000

Issuance of warrants pursuant to consulting agreement														943,000								943,000

Issuance of common stock resulting from exercise of stock options		216,616		217																		217

Foreign currency translation																	17,538					17,538

Net loss																			(4,945,477	)		(4,945,477	)

Balance at September 30, 2018		71,363,953	$	71,364		1,000,000	$	1,000		13,784,201	$	13,784	$	81,212,979		$	17,538	$	(23,187,185	)	$	58,129,480

		PAGE
PART I	FINANCIAL INFORMATION	1

ITEM 1.	Financial Statements	1
	Condensed Consolidated Balance Sheets (unaudited) as of ~~September~~June 30, ~~2018 (unaudited)~~2019 and December 31, ~~2017 (audited)~~2018	1
	Condensed Consolidated Statements of Operations for the Three and ~~Nine~~Six Months Ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018 (unaudited)	2
	Condensed Consolidated Statements of ~~Comprehensive Loss for the Three and Nine Months Ended September 30, 2018 and 2017 (unaudited)~~	3
	~~Condensed Consolidated Statement of~~ Changes in Shareholders’ Equity for the ~~Nine~~Three and Six Months Ended ~~September~~June 30, 2019 and 2018 (unaudited)	43
	Condensed Consolidated Statements of Cash Flows for the ~~Nine~~Six Months Ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018 (unaudited)	57
	Notes to the Condensed Consolidated Financial Statements ~~(Revised)~~	68
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3441
ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	3949
ITEM 4.	Controls and Procedures	3949

PART II	OTHER INFORMATION	4151

ITEM 1.	Legal Proceedings	4151
ITEM 1A.	Risk Factors	4151
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4151
ITEM 3	Defaults upon Senior Securities	4151
ITEM 4.	Mine Safety Disclosures	4151
ITEM 5.	Other Information	4151
ITEM 6.	Exhibits	4252

SIGNATURES		4353

	September 30,			December 31,			June 30,			December 31,
	2018			2017			2019			2018
ASSETS	(Unaudited)			(Audited)
Current assets:
Cash	$	464,992		$	868,554		$	800,015		$	285,761
Accounts receivable, net		1,152,337			610,313			1,640,996			1,184,923
Prepaid expenses and other current assets								540,342			409,800
Costs & earnings in excess of billings		24,792			40,847			12,017			42,869
Total current assets		1,642,121			1,519,714			2,993,370			1,923,353

Property and equipment, net		280,524			110,634			545,818			349,518
Intangible assets, net		19,777,516			3,042,259			16,312,706			18,604,078
Goodwill		39,913,559			664,329			40,735,366			39,913,559
Deposits and other assets		518,124			68,313			1,413,493			146,990
Promissory note receivable								75,000			-
Total assets	$	62,131,844		$	5,405,249		$	62,075,753		$	60,937,498

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities:
Accounts payable and accrued liabilities	$	1,319,261		$	598,637		$	2,463,136		$	1,702,713
Advances from related parties		55,250			124,750			-			45,250
Billings in excess of costs		3,786			20,191			126,862			155,192
Deferred rent		3,264			9,667			-			2,937
Notes payable, current portion		7,582			11,179			24,805			24,805
Obligation pursuant to acquisition		253,334			559,103			75,000			201,667
Convertible notes payable, net of discount		132,625			812,393			423,700			187,177
Convertible note payable - related party		-			243,506
Promissory notes		250,000			-
Convertible notes payable, net of discount - related party								1,395,623			-
Due to related party								-			32,489
Contingent consideration		909,292			-			-			908,604
Obligation to issue warrants		994,809			2,429,569
Warrant liability								2,199,266			896,171
Total current liabilities		3,929,203			4,808,995			6,708,392			4,157,005

Long-term liabilities
Long-term liabilities:
Notes payable, net of current portion		73,161			53,293			40,232			51,554
Other long-term liabilities								962,716			-
Total long-term liabilities		73,161			53,293			1,002,948			51,554

Total liabilities		4,002,364			4,862,288			7,711,340			4,208,559

Shareholders’ equity:
Preferred stock (Class A), $0.001 par value, 3,000,000 shares authorized; 1,000,000 issued and outstanding as of September 30, 2018 and December 31, 2017		1,000			1,000
Preferred stock (Class B), $0.001 par value, 17,000,000 shares authorized; 13,784,201 issued and outstanding as of September 30, 2018 and December 31, 2017		13,784			13,784
Common stock; par value $0.001; 200,000,000 shares authorized; 71,363,953 shares issued and outstanding as of September 30, 2018; 28,771,402 shares issued and outstanding as of December 31, 2017		71,364			28,771
Preferred stock (Class A), $0.001 par value, 3,000,000 shares authorized; 1,000,000 issued and outstanding as of June 30, 2019 and December 31, 2018								1,000			1,000	��
Preferred stock (Class B), $0.001 par value, 17,000,000 shares authorized; 13,784,201 issued and outstanding as of June 30, 2019 and December 31, 2018								13,784			13,784
Common stock; par value $0.001; 200,000,000 shares authorized; 75,747,718 shares issued and outstanding as of June 30, 2019; 72,660,825 shares issued and outstanding as of December 31, 2018								75,748			72,660
Additional paid-in capital		81,212,979			18,741,114			86,489,136			82,831,014
Accumulated other comprehensive income		17,538			-			21,648			17,991
Accumulated deficit		(23,187,185	)		(18,241,708	)		(32,236,903	)		(26,207,510	)
Total shareholders’ equity		58,129,480			542,961			54,364,413			56,728,939
Total liabilities and shareholders’ equity	$	62,131,844		$	5,405,249		$	62,075,753		$	60,937,498

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,						For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2018 (Revised)			2017			2018			2017			2019			2018			2019			2018

Security and guarding	$	1,141,676		$	1,129,746		$	3,432,651		$	2,837,145		$	1,347,529		$	1,197,201		$	2,552,240		$	2,290,975
Systems installation		318,850			-			454,113			-			174,067			100,699			202,608			135,263
Software		1,653,195			-			2,229,337			-			2,377,277			576,142			4,515,132			576,142
Total revenues	$	3,113,721		$	1,129,746		$	6,116,101		$	2,837,145		$	3,898,873		$	1,874,042		$	7,269,980		$	3,002,380
Cost of revenue		1,880,061			814,031			3,892,716			2,192,366			1,996,699			1,560,387			3,921,918			2,351,092
Gross margin		1,233,660			315,715			2,223,385			644,779			1,902,174			313,655			3,348,062			651,288

Operating expenses:
Selling, general and administrative		802,724			269,143			1,678,603			649,973			1,170,491			527,999			2,107,369			875,879
Salaries and wages		1,888,155			315,316			4,308,994			602,254			1,214,969			1,216,082			2,466,546			2,082,402
Professional and legal fees		473,651			261,098			1,362,205			641,958			792,101			268,795			1,480,556			888,554
Depreciation and amortization		806,611			194,347			1,869,889			292,757			1,190,336			864,375			2,355,977			1,063,278
Loss on impairment of Goodwill														-			-			-			664,329
Total operating expenses		3,971,141			1,039,904			9,219,691			2,186,942			4,367,897			2,877,251			8,410,448			5,574,442

Loss from operations		(2,737,481	)		(724,189	)		(6,996,306	)		(1,542,163	)		(2,465,723	)		(2,563,596	)		(5,062,386	)		(4,923,154	)

Other income (expenses):
Change in fair value of convertible note		(17,880	)		115,000			679,766			(210,000	)		845,622			120,630			(142,341	)		697,646
Change in fair value of convertible note - related party		-			(34,725	)		118,506			8,971			2,818,739			-			(705,270	)		118,506
Change in fair value of obligation to issue warrants		136,920			531,395			1,434,760			406,604
Change in fair value of warrant liability														3,871,101			321,161			2,238,145			1,297,840
Change in fair value of contingent consideration		(131,994	)		(25,078	)		(131,994	)		10,186			256,650			-			(880,050	)		-
Loss on induced conversion of convertible note		-			-			-			(1,503,876	)
Loss on extinguishment of debt		-			-			-			(4,611,395	)
Loss on impairment of Goodwill		-			-			(664,329	)		-
Loss on issuance of warrants														-			-			(787,209	)		-
Gain on reduction of obligation pursuant to acquisition		50,361			-			607,415			-			-			290,441			-			557,054
Interest income/(expense), net		21,622			(117,760	)		6,705			(678,354	)
Interest (expense) income														(514,081	)		3,016			(690,282	)		(14,917	)
Other income (expenses)		59,029			468,832			2,050,829			(6,577,864	)		7,278,031			735,248			(967,007	)		2,656,129

Net loss	$	(2,678,452	)	$	(255,357	)	$	(4,945,477	)	$	(8,120,027	)
Net income (loss)													$	4,812,308		$	(1,828,348	)	$	(6,029,393	)	$	(2,267,025	)

Other comprehensive income:
Other comprehensive (loss) income:
Changes in foreign currency translation adjustment		17,538			-			17,538			-			(590	)		-			3,657			-
Total other comprehensive income		17,538			-			17,538			-
Total comprehensive loss		(2,660,914	)		(255,357	)		(4,927,939	)		(8,120,027	)
Total other comprehensive (loss) income														(590	)		-			3,657			-
Total comprehensive income (loss)														4,811,718			(1,828,348	)		(6,025,736	)		(2,267,025	)

Convertible preferred stock beneficial conversion feature accreted as a deemed dividend		-			(8,044,958	)		(22,202,194	)		(11,200,845	)		-			(7,203,689	)		-			(22,202,194	)

Net loss attributable to common shareholders	$	(2,660,914	)	$	(8,300,315	)	$	(27,130,133	)	$	(19,320,872	)
Net income (loss) attributable to common shareholders													$	4,811,718		$	(9,032,037	)	$	(6,025,736	)	$	(24,469,219	)

Net loss per share attributable to common shareholders:
Net income (loss) per share attributable to common shareholders:
Basic	$	(0.04	)	$	(0.29	)	$	(0.57	)	$	(0.68	)	$	0.06		$	(0.21	)	$	(0.08	)	$	(0.68	)
Diluted	$	(0.04	)	$	(0.29	)	$	(0.57	)	$	(0.68	)	$	(0.03	)	$	(0.21	)	$	(0.08	)	$	(0.68	)

Weighted average common shares outstanding:
Basic		70,420,857			28,644,522			47,598,820			28,592,643			75,470,238			42,673,528			74,324,689			35,907,118
Diluted		70,420,857			28,644,522			47,598,820			28,592,643			81,236,678			42,673,528			74,324,689			35,907,118

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2018 (Revised)			2017			2018			2017

Net loss, as reported	$	(2,678,452	)	$	(255,357	)	$	(4,945,477	)	$	(8,120,027	)
Other comprehensive income:
Foreign currency translation adjustments		17,538			-			17,538			-
Comprehensive loss	$	(2,660,914	)	$	(255,357	)	$	(4,927,939	)	$	(8,120,027	)

	Previously Reported			Adjustments			Revised
Condensed Consolidated Balance Sheet as of December 31, 2017
Convertible notes payable, net of discount	$	1,301,004		$	(488,611	)	$	812,393
Total liabilities	$	5,350,899		$	(488,611	)	$	4,862,288
Preferred Shares (Class B) Outstanding		13,306,599			477,602			13,784,201
Preferred Shares (Class B) Par Amount	$	13,307		$	477		$	13,784
Additional Paid in Capital	$	3,923,234		$	552,023		$	4,475,257
Accumulated Deficit	$	(18,177,819	)	$	(63,889	)	$	(18,241,708	)
Total Shareholders’ Equity	$	54,350		$	488,611		$	542,961
Total Liabilities and Shareholders’ Equity	$	5,405,249		$	-		$	5,405,249

	Previously Reported		Adjustments			As revised
Condensed Consolidated Statement of Operations for the Six Months Ended June 30, 2018
Revenue	$	3,340,817	$	(338,437	)	$	3,002,380
Cost of Revenue	$	2,689,529	$	(338,437	)	$	2,351,092

	Total Goodwill
Balance at January 1, 2018	$	664,329
Impairment of goodwill		(664,329	)
Goodwill attributable to Biotrack acquisition		39,135,007
Goodwill attributable to Engeni acquisition		778,552
Balance at September 30, 2018	$	39,913,559

	September 30, 2018			December 31, 2017
Note Five, 5% convertible promissory note, fixed secured, maturing May 16, 2018	$	132,625		$	812,393
		132,625			812,393
Less: Current portion		(132,625	)		(812,393	)
Long-term portion	$	-		$	-

For the Nine Months Ended September 30, 2018
Issuance Date	Beneficial Conversion Feature Term (months)	Number of shares		Fair Value of Beneficial Conversion Feature		Amount accreted as a deemed dividend at December 31, 2017			Amount accreted as a deemed dividend for the Nine Months Ended September 30, 2018			Unamortized Beneficial Conversion Feature
May 17, 2017	12		7,318,084	$	25,247,098	$	(15,779,436	)	$	(9,467,661	)	$	-
July 29, 2017	9.5		1,680,000		6,804,000		(3,674,634	)		(3,129,366	)		-
August 29, 2017	8.5		369,756		1,148,263		(556,190	)		(592,073	)		-
September 15, 2017	8		462,195		1,435,329		(648,601	)		(786,728	)		-
October 11, 2017	7		462,195		1,121,036		(426,309	)		(694,727	)		-
October 31, 2017	6.5		1,042,337		1,735,641		(548,570	)		(1,187,071	)		-
December 19, 2017	5		2,449,634		6,921,347		(576,779	)		(6,344,568	)		-
Total			13,784,201	$	44,412,714	$	(22,210,519	)	$	(22,202,194	)	$	-

	Shares Underlying Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)
Outstanding at January 1, 2018		414,854		$	0.001		2.42

Granted		490,000		$	1.92		0.51

Options assumed pursuant to acquisition		8,132,410		$	0.72		2.17

Forfeited and expired		(80,979	)	$	0.001

Exercised		(216,616	)	$	0.001

Outstanding at September 30, 2018		8,739,669		$	0.001		2.70

Vested options at September 30, 2018		8,466,285		$	0.69		2.19

For the Nine Months Ended September 30, 2018
	Warrant Shares		Weighted Average Exercise Price
Balance at January 1, 2018		2,732,073	$	0.23

Warrants granted		575,000	$	0.01

Balance at September 30, 2018		3,307,073	$	0.19

	Amount
Balance as of January 1, 2018	$	2,429,569

Change in fair value of liability to issue warrants	$	(1,434,760	)

Balance as of September 30, 2018	$	994,809

	Amount
Balance as of July 1, 2018	$	1,131,729

Change in fair value of liability to issue warrants	$	(136,920	)

Balance as of September 30, 2018	$	994,809